

CURRICULUM VITAE

NAME AND DEGREES Ecaterina E Dumbrava, M.D.

OFFICE ADDRESS The University of Texas MD Anderson Cancer Center
1400 Holcombe Boulevard
FC8.2024
Unit 455
Houston, TX 77030

OFFICE PHONE 713-792-3934

OFFICE FAX 713-792-3535

OFFICE EMAIL eeileana@mdanderson.org

CURRENT APPOINTMENTS

Aug 2018–Present Assistant Professor
Investigational Cancer Therapeutics
The University of Texas MD Anderson Cancer Center

LICENSES AND CERTIFICATIONS

Aug 2022–Aug 2025 Texas Medical Board
Licensure

Aug 2021–Aug 2022 Texas Medical Board
Licensure

Aug 2020–Aug 2021 Texas Medical Board
Licensure

Aug 2019–Aug 2020 Texas Medical Board
Licensure

Aug 2018–Aug 2019 Texas Medical Board
Licensure

Jul 2016–Jun 2018 Texas Medical Board
Licensure

Sep 2014–Present French Board of Medical Oncology
Board Certification, 94/18324

Sep 2014–Present French Board of Medical Oncology
Licensure, 94/18324

Mar 2014–Present Romanian Board of Medical Oncology
Board Certification

EDUCATION, EXPERIENCE, AND SERVICE

DEGREES OBTAINED

Jun 2015 M.Sc., Master of Science Health Biology-Oncology/ Early Drug Development
Paris South University; Orsay, France

Sep 2008 MD
University of Medicine and Pharmacy "Iuliu-Hatieganu"; Cluj-Napoca, Romania

POSTGRADUATE TRAINING

Feb 2018–Mar 2018	Research Fellowship NIH/NCI Cancer Therapy Evaluation Program (CTEP); Houston
Jul 2017–Jun 2018	Clinical Fellowship (Chief fellow), Department of Investigational Cancer Therapeutics MD Anderson Cancer Center The University of Texas; Houston, Texas
Jul 2016–Jun 2017	Clinical Fellowship, Department of Investigational Cancer Therapeutics MD Anderson Cancer Center The University of Texas; Houston, Texas
Jan 2015–Dec 2015	Postdoctoral Fellowship, Translational Molecular Pathology Department MD Anderson Cancer Center The University of Texas; Houston, Texas
Nov 2013–Oct 2014	Research Fellowship, Medical Oncology Gustave Roussy Cancer Campus; Villejuif, France
May 2011–Oct 2013	Clinical Fellowship, Medical Oncology Gustave Roussy Cancer Campus; Villejuif, France
May 2009–May 2011	Clinical Residency, Medical Oncology/Internal Medicine Assistance Publique Hôpitaux de Marseille; Marseille, France
Jan 2009–Apr 2009	Clinical Residency, Internal Medicine/Medical Oncology Third Medical Hospital; Cluj-Napoca, Romania

FACULTY ACADEMIC APPOINTMENTS

Aug 2018–Present	Assistant Professor Investigational Cancer Therapeutics The University of Texas MD Anderson Cancer Center
------------------	---

OTHER PROFESSIONAL POSITIONS

Aug 2022	Advisory Board Member Summit Therapeutics; Houston, Texas
Jun 2022	Speaker PMV Pharma; Houston, Texas
May 2022	Advisory Board Member Orum Therapeutics; Houston, Texas
2022	Advisory Board Member Mersana Therapeutics; Houston, Texas
2021	Consultant Catamaran Bio; Houston, TX
Dec 2020–Sep 2021	Advisory Board Member BOLT Therapeutics; Houston, Texas
Jan 2019–Present	Member Andrew M. McDougall Brain Metastasis Clinic; Houston, TX

ADMINISTRATIVE LEADERSHIP POSITIONS

Dec 01, 2023–Present	Director for Investigational Cancer Therapeutics/Phase 1, Cancer Network Research The University of Texas MD Anderson Cancer Center
Jun 01, 2023–Present	Inpatient Unit Lead Investigational Cancer Therapeutics

The University of Texas MD Anderson Cancer Center

HONORS AND PRIZES

- 2018 K12 Paul Calabresi Advanced Scholar
NCI
- 2018 Scholar in Training Award for Targeting PI3K/mTOR signaling AACR Conference
American Association for Cancer Research
- 2017 AACR Scholar-in-Training Award
American Association for Cancer Research
- 2017 ASCO Merit Award
American Society of Clinical Oncology
- 2012 ESMO examination in Medical Oncology
ESMO
- 2006 ERASMUS Scholarship
University Hospitals of Marseille

COMMITTEE SERVICE

- 2021–2022 Lead, Institutional Committee
Brain Metastasis Algorithm Working Group
The University of Texas MD Anderson Cancer Center
- 2021–Present Lead, Institutional Committee
HER2 Working Group ICT Department
The University of Texas MD Anderson Cancer Center
- 2019–Present Associate Scientific Member, Institutional Committee
Institutional Board Review
The University of Texas MD Anderson Cancer Center
- 2019–Present Member, Institutional Committee
Secondary Germline Findings Working Group
The University of Texas MD Anderson Cancer Center
- 2018–Present Member, Institutional Committee
CARTOX Committee
The University of Texas MD Anderson Cancer Center
- 2017–2018 Member, Institutional Committee
GME Diversity and Disparities Committee
The University of Texas MD Anderson Cancer Center
- 2017–2018 Secretary, Institutional Committee
House Staff Senate
The University of Texas MD Anderson Cancer Center
- 2017–Present Member, Institutional Committee
Clinical Effectiveness Advisory Committee
The University of Texas MD Anderson Cancer Center

PROFESSIONAL SOCIETIES

- 2021–Present Secondary Germline Findings Working Group

2021–Present Member
- 2021–Present Adoptive Cell Therapy Platform and CARTOX Program

2021–Present Member

- 2019–Present Society for Immunotherapy of Cancer-SITC
2019–Present Member
- 2019–Present Institutional Board Review MD Anderson Cancer Center
Houston, TX
2019–Present Associate Scientific Member
- 2018–Present CARTOX committee MD Anderson Cancer Center
Houston, TX
2018–Present Member
- 2017–2018 House Staff Senate MD Anderson Cancer Center
Houston, TX
2017–2018 Secretary
- 2017–2018 GME Diversity and Disparities Committee MD Anderson Cancer Center
Houston, TX
2017–2018 Member
- 2017–Present Clinical Effectiveness Subcommittee MD Anderson Cancer Center
Houston, TX
2017–Present Member
- 2014–Present American Association for Cancer Research - AACR
2014–Present Member
- 2013–2016 French Residents and Fellows Association for Teaching and Research in Oncology
- AERIO
2013–2016 Member
- 2012–Present American Society of Clinical Oncology - ASCO
2012–Present Member
- 2012–Present European Society of Medical Oncology - ESMO
2012–Present Member

EDITORIAL ACTIVITIES

- 2023–Present Member of Editorial Review Board
Editorial Board of Journal of Immunotherapy and Precision Oncology (JIPO)
- 2020–2021 Associate Scientific Advisors (ASAs)
Science Translational Medicine

PEER REVIEW ACTIVITIES

- 2022–Present Journal Reviewer
British Journal of Cancer

2020 Journal Reviewer
Molecular Oncology

2020 Journal Reviewer
Oncotarget

2019–2020 Journal Reviewer
International Journal of Cancer

2019–2021 Journal Reviewer
Journal of Immunotherapy and Precision Oncology

OTHER ACTIVITIES

Fluent in English, French, Romanian, and Hungarian languages

RESEARCH PROJECTS

GRANTS, CONTRACTS, AND SPONSORED

RESEARCH AGREEMENTS

Current, May 13, 2023–Present Performance Improvement Demonstration Project: Optimizing Integration of Molecular Testing in Lung, Thyroid & Breast Cancer
Lilly USA, A-29694
Co-Investigator

Current, Sep 01, 2022–Present Moon Shot Project: p53 Reactivation in p53 Y220C Mutated Solid Tumors
Institutional Funding, The University of Texas MD Anderson Cancer Center
Principal Investigator (\$ 269,954 incl. indirect costs; \$269,954/year)

Past, Sep 01, 2021–Apr 30, 2022 Study to Establish the Diagnostic Performance of 18F-Fluciclovine Positron Emission Tomography (PET) in Detecting Recurrent Brain Metastases after Radiation Therapy
Blue Earth Diagnostics
Collaborator

Past, Aug 01, 2018–Jun 03, 2020 Paul Calabresi Clinical Oncology Research Career Development Program
NIH/NCI, K12 Award, K12CA088084-19
Principal Investigator (\$ 277,920 incl. indirect costs; \$151,179/year)
Major goals: 1) To identify, select and recruit a diverse group of talented, dedicated and highly-motivated clinical scholars who are destined to become leaders in the area of clinical and translational research. 2) To provide dedicated time, optimal mentorship, formal education, experience in developing hypothesis-driven clinical trials with relevant correlates, and a monthly Master Class. 3) To evaluate both short- and long-term outcomes of the Calabresi Scholars program

Unknown, Jan 01, 2021–Mar 31, 2024 ALRN-6924 (MDM2/MDMX inh) and paclitaxel in patients with advanced or metastatic solid tumors with TP53 WT, including ER+ breast cancer
Gateway for Cancer Research, G-20-300
Principal Investigator (\$ 798,428 incl. indirect costs; \$246,137/year)

CLINICAL PROTOCOLS

Current A phase 1 study of FT825/ONO-8250, an off-the-shelf CAR T-Cell therapy, with or without Monoclonal antibodies, in HER2-positive or other Advanced Solid Tumors, Fate Therapeutics, 2023-0624
Principal Investigator

Current A Phase 1a/1b study investigating the safety, tolerability, pharmacokinetics, and preliminary antitumor activity BGB-A538, alone and in combination with

	Tislelizumab with or without Ociperlimab In patients with selected advanced or metastatic solid tumors, BeiGene, 2023-0611 Principal Investigator
Current	A phase 1/2 study investigating the safety and efficacy of autologous TAC T cells in subjects with unresectable, locally advanced or metastatic Claudin 18.2+ solid tumors, Triumvira Immunologics, Inc, 2023-0145 Principal Investigator
Current	Single patient clinical protocol of PC14586 for a patient with colorectal cancer harboring a TP53 Y220C, NCI/CTEP/UM1, 2022-0795 Principal Investigator
Current	SPIND: Compassionate use of the investigational drug Zanidatamab (ZW25) in patients with HER2 positive advanced solid tumors, The University of Texas MD Anderson Cancer Center, 2024-0272 Principal Investigator
Current, 2024–Present	A phase I/II study of VLS-1488 (an oral KIF18A inhibitor) in subjects with advanced cancer, Volastra Therapeutics, Inc., 2023-0402 Principal Investigator
Current, 2024–Present	A Phase 1/2A, multicenter, first-in-human, open-label clinical trial evaluating MDX2001 monotherapy in patients with advanced solid tumors, ModeX Therapeutics, 2023-0796 Principal Investigator
Current, 2024–Present	A phase I/II open label study to evaluate the safety, cellular kinetics, and efficacy of AZD0754, a chimeric antigen receptor (car) t-cell therapy directed against STEAP2, in adult participants, AstraZeneca Pharmaceuticals, 2023-0279 Principal Investigator
Current, 2024–Present	A long-term follow-up master protocol for participants who received cell or gene therapies in other AstraZeneca studies (LOCUS), AstraZeneca UK Limited, 2023-1006 Principal Investigator
Current, 2024–Present	An open-label, phase 1, multicenter study to evaluate the safety and preliminary anti-tumor activity of NT-175 in human leukocyte Antigen-A*02:01-Positive adult subjects with unresectable, advanced and/or metastatic solid tumors that are positive for the TP53 R175H mutation, Neogene Therapeutics, Inc., 2023-0925 Principal Investigator
Current, 2023–Present	A Phase 1, open-label, dose escalation and dose expansion study evaluating AO 252, a protein protein interaction inhibitor of TACC3, in advanced solid tumors including triple negative breast cancer (TNBC), high-grade serous ovarian carcinoma (HGSOC), and endometrial cancer, A2A Pharmaceuticals, 2023-0162 Principal Investigator

- Current, 2023–Present A phase II study of Tucatinib and Ado-trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic solid tumors and metastases to brain (TUCATEMEB)
R01, Investigator-Initiated Trial/ The University of Texas MD Anderson Cancer Center, 2021-0899
Principal Investigator
- Current, 2023–Present NCI10459 - Phase I trial of DS-8201a (Trastuzumab Deruxtecan) in combination with Neratinib in solid tumors with HER2 alterations
NCI/CTEP/UM1, 2022-0765
Principal Investigator
- Current, 2023–Present A phase 2 basket study of Disitamab Vedotin in adult subjects with previously treated, locally-advanced unresectable or metastatic solid tumors that express HER2, Seagen, Inc, 2023-0372
Principal Investigator
- Current, 2023–Present Phase 1 dose escalation and expansion Study of TROP2 CAR Engineered IL-15-transduced Cord Blood-derived NK Cells in Patients with Advanced Solid Tumors (TROPIKANA), The University of Texas MD Anderson Cancer Center, 2023-0161
Principal Investigator
- Current, 2022–Present A Phase 1 Dose Escalation and Expanded Cohort Study of P-MUC1C-ALLO1 in Adult Subjects with Advanced or Metastatic Solid Tumors
Poseida Therapeutics, Inc, 2021-0944
Principal Investigator
- Current, 2022–Present A phase IA/IB, open label, dose-escalation study of the combination of BI 907828 with BI 754091 (ezabenlimab) and BI 754111 and the combination of BI 907828 with BI 754091
Boehringer Ingelheim Pharmaceutical, Inc, 2022-0393
Principal Investigator
- Current, 2022–Present An open-label, multicenter, phase 1b, first in human, dose escalation and expansion study of XMT-2056 in participants with advanced/recurrent solid tumors that express HER2
Mersana Therapeutics, Inc., 2022-0522
Principal Investigator
- Current, 2022–Present A Phase 1/2 open-label, first-in-human, dose escalation and expansion study for the evaluation of safety, pharmacokinetics, pharmacodynamics, and anti-tumor activity of SAR444200-based regimen in participants with advanced solid tumors
Sanofi US Services Inc, 2022-0044
Principal Investigator
- Current, 2022–Present A First-in-Human, Phase 1/2, Dose Escalation Study of BOXR1030 T cells in Subjects with Advanced GPC3-Positive Solid Tumors
Sotio Biotech, LLC, 2021-0939
Principal Investigator
- Current, 2021–Present A Phase I/II Trial Investigating Safety and Efficacy of Autologous TAC T Cells Targeting HER2 in Relapsed or Refractory Solid Tumors (TACTIC-2)
Triumvira Immunologics, 2020-1161

Principal Investigator

- Current, 2021–Present A Phase 2 Basket Study of Milademetan in Advanced/Metastatic Solid Tumors
Rain Oncology, 2021-0613
Principal Investigator
- Current, 2021–Present A Phase 1 Open-Label, First-in-Human, Single Agent, Dose Escalation and
Expansion Study for the Evaluation of Safety, Pharmacokinetics,
Pharmacodynamics and Anti-Tumor Activity of SAR443216 in Participants with
Relapsed/Refractory HER2+ Solid Tumors
Sanofi US Services Inc, 2021-0455
Principal Investigator
- Current, 2020–Present Immune Checkpoint Blockade for Kidney Transplant Recipients with Selected
Unresectable or Metastatic Cancers
NCI, 2020-0058
Principal Investigator
- Current, 2020–Present Phase 1/2 study of APR-246 in Combination with Pembrolizumab in Subjects
with Solid Tumor Malignancies
Aprea Therapeutics, 2020-0443
Principal Investigator
- Current, 2020–Present A Phase 1/2 Open-label, Multicenter Study to Assess the Safety, Tolerability,
Pharmacokinetics, Pharmacodynamics, and Efficacy of PC14586 in Patients with
Advanced Solid Tumors Harboring a p53 Y220C Mutation
PMV Pharma, 2020-0833
Principal Investigator
- Current, 2020–Present A phase 1/2 study evaluating the safety, tolerability and preliminary antitumor
activity of COM701 in combination with BMS-986207 (anti-TIGIT antibody) and
nivolumab in subjects with advanced solid tumors
Compugen Ltd, 2020-0755
Principal Investigator
- Current, 2020–Present Phase 1b Trial of the Combination of the ATR Inhibitor BAY1895344 and PI3K
Inhibitor Copanlisib in Molecularly Selected Patients with Advanced Solid
Tumors (COPABAY)
Strategic Alliance/Investigator Initiated, 2020-0706
Co-Principal Investigator
- Current, 2020–Present A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies
Seagen, 2020-1277
Principal Investigator
- Current, 2020–Present An Open-label, Single-arm, Single-dose, Prospective, Multicenter Phase 3 Study
to Establish the Diagnostic Performance of 18F-Fluciclovine Positron Emission
Tomography (PET) in Detecting Recurrent Brain Metastases after Radiation
Therapy (REVELATE), 2020-0690
Co-Principal Investigator

- Current, 2020–Present A Phase 1 Study of Safety and Tolerability of COM902 in subjects with advanced Malignancies
Compugen Ltd, 2020-0195
Principal Investigator
- Current, 2020–Present A Phase 1 Open-Label, Multi-Center First in Human Study of TnMUC1-Targeted Genetically-Modified Chimeric Antigen Receptor T Cells in Patients with Advanced TnMUC1-Positive Solid Tumors and Multiple Myeloma
Tmunity Therapeutics, Inc., 2020-0319
Co-Principal Investigator
- Current, 2019–Present A Phase 1 Study of LY3434172, a Bispecific Antibody Monotherapy in Advanced Solid Tumors
Eli Lilly, 2019-0156
Co-Principal Investigator (Yap, Timothy Anthony PI)
- Current, 2019–Present A Phase 1 study of an autologous ACTR T cell product in combination with trastuzumab, a monoclonal antibody, in subjects with HER2-positive advanced malignancies
Unum Therapeutics, Inc., 2019-0117
Principal Investigator
- Current, 2019–Present A Phase 1 Dose-Escalation Study of TJ004309 in Combination with Atezolizumab (Tecentriq) in Patients with Advanced or Metastatic Cancer
TRACON Pharmaceuticals, Inc, 2019-0108
Principal Investigator
- Current, 2019–Present A Phase 1B/2 Open Label, Dose Escalation and Expansion Study of the Glutaminase Inhibitor CB-839 in Combination with the PARP Inhibitor Talazoparib in Patients with Advanced or Metastatic Solid Tumors
Calithera, 2019-0048
Collaborator (Meric-Bernstam, Funda PI)
- Current, 2019–Present NCI10204: A Phase 1b Study of Nivolumab in Patients with Autoimmune Disorders and Advanced Malignancies (AIM-NIVO), National Cancer Institute (NCI), NCI10204
Principal Investigator
- Current, 2019–Present A Phase 1 Dose Escalation with Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMV564 in Subjects with Advanced Solid Tumors
Amphivena Therapeutics, Inc., 2019-0552
Co-Principal Investigator
- Current, 2019–Present A Phase 1b Biomarker-Driven Combination Trial of Copanlisib, Olaparib, and MEDI4736 (Durvalumab) in Patients with Advanced Solid Tumors
NCI/CTEP, NCI10217
Collaborator (Yap, Timothy PI)
- Current, 2019–Present Phase IB Combination Study of Copanlisib and Nivolumab in Advanced Solid Tumors and Lymphomas
NCI, NCI10145
Co-Principal Investigator

- Current, 2019–Present Phase 1/2 Study of RTX-240 as Monotherapy and in Combination with Pembrolizumab, 2019-1238
Co-Principal Investigator
- Current, 2019–Present An open-label phase 1b study to determine the maximum tolerated and/or recommended phase 2 dose of the ATR inhibitor BAY 1895344 in combination with PARP inhibitor niraparib, in patients with recurrent advanced solid tumors and ovarian cancer
Bayer HealthCare Pharmaceuticals Inc., 2019-0471
Co-Principal Investigator (Yap, Timothy PI)
- Current, 2019–Present A Phase 1/2 First-in-Human Study of the Safety and Efficacy of IMC-F106C as a Single Agent and in Combination with Checkpoint Inhibitors in HLA-A*02:01-Positive Participants with Advanced PRAME-Positive Cancers
Immunocore LTD., 2019-1173
Principal Investigator
- Current, 2019–Present Phase 1 Study of BDC-1001 as a Single Agent and in Combination with Pembrolizumab in Patients with Advanced and HER2 Expressing Solid Tumors
BOLT Biotherapeutics, 2019-1111
Principal Investigator
- Current, 2019–Present A Phase 1/2 Study of ALKS 4230 Administered Subcutaneously as Monotherapy and in Combination with Pembrolizumab in Subjects With Advanced Solid Tumors- ARTISTRY-2 (001)”
Alkermes, Syneos Health, 2019-0657
Collaborator (Piha-Paul, SA PI)
- Current, 2019–Present A Phase I Dose Escalation Study of NMS-03305293 in Adult Patients with Selected Advanced/Metastatic Solid Tumors
Nerviano Medical Services, 2019-0443
Co-Principal Investigator (Fu Siqing PI)
- Current, 2019–Present A Phase 1/2 Dose Escalation Study of AP-002 In Patients with Advanced or Recurrent Solid Tumors
Altum Pharmaceuticals, 2019-0196
Collaborator (Subbiah, Vivek PI)
- Current, 2019–Present A phase 1 study of SGN-CD47M in patients with advanced solid tumors
Seattle Genetics, 2019-0001
Collaborator (Piha-Paul, Sarina PI)
- Current, 2019–Present An Open-Label, Multicenter, First-in-Human, Dose-Escalation, Phase 1 Study of INBRX-105 in Patients with Locally Advanced or Metastatic Solid Tumors, Hodgkin or Non-Hodgkin Lymphoma
Inhibrx, Inc, 2019-0303
Co-Principal Investigator (Subbiah, Vivek PI)
- Current, 2019–Present Phase I/IIA Safety and Efficacy Study of IMSA101 in Patients with Advanced Treatment-Refractory Malignancies
ImmuneSensor Therapeutics, 2019-0397

Co-Principal Investigator (Yap, Timothy PI)

- Current, 2019–Present A Phase 1, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB-3312 in Adult Patients with Advanced Solid Tumors
Jacobio Pharmaceuticals, 2019-0495
Collaborator (Piha-Paul, SA PI)
- Current, 2019–Present A multicenter, non-randomized, open-label Phase 1b study to determine the maximum tolerated and recommended Phase II dose of the ATR Inhibitor BAY 1895344 in combination with pembrolizumab and to characterize its safety, tolerability, pharmacokinetics and preliminary anti-tumor activity in patients with advanced solid tumors
Bayer, 2019-0418
Collaborator (Yap, Timothy PI)
- Current, 2019–Present A Phase 1 Dose Escalation With Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMV564 in Subjects with Advanced Solid Tumors
Amphivena Therapeutics, 2019-0552
Collaborator (Piha-Paul, SA PI)
- Current, 2019–Present A Phase 1, Open-label, Multicenter Study of SYN1891 Administered by Intratumoral Injection to Patients with Advanced/Metastatic Solid Tumors and Lymphoma Alone and in Combination with Atezolizumab
Synlogic Operating Company, Inc., 2019-0576
Collaborator (Janku, Filip PI)
- Current, 2019–Present A Phase 1a/1b Study of LY3435151 Administered to Patients with Advanced Solid Tumors
Eli Lilly, 2019-0635
Collaborator (Yap, Timothy PI)
- Current, 2019–Present A Phase I/II Dose-Escalation and Cohort-Expansion Study of Intravenous eFT226 in Subjects with Selected Advanced Solid Tumor Malignancies
eFFECTOR Therapeutics, 2019-0668
Co-Principal Investigator (Meric-Bernstam, Funda PI)
- Current, 2019–Present A Phase 1, Open-label, Dose-escalation and Expansion Study of MEDI1191 Administered Intratumorally as Monotherapy and in Combination with Durvalumab in Subjects with Advanced Solid Tumors
MedImmune, 2019-0204
Collaborator (Subbiah, Vivek PI)
- Current, 2019–Present A Phase 1b/2, Open Label, Dose Escalation and Expansion Study of the Glutaminase Inhibitor Telaglenastat (CB-839) in Combination with the CDK4/6 Inhibitor Palbociclib in Patients with Advanced or Metastatic Solid Tumors
Calithera Biosciences, Inc, 2019-0349
Collaborator (Meric-Bernstam, Funda PI)
- Current, 2019–Present Phase 1/2 Open-Label Study of the Safety, Pharmacokinetics, and Preliminary Activity of ASTX295 in Subjects with Wild-Type TP53 Advanced Solid Tumors
Astex Therapeutics, 2019-0273

Principal Investigator

- Current, 2019–Present A First-in-Humans Dose Finding Study for an Aryl Hydrocarbon Receptor Inhibitor (AhRi) in Patients With Advanced Cancer
Bayer HealthCare Pharmaceuticals Inc, 2019-0440
Principal Investigator
- Current, 2019–Present A Phase 1b Study of Nivolumab in Patients with Autoimmune Disorders and Advanced Malignancies (AIM-NIVO)
NCI/CTEP/UM1, NCI10204
Principal Investigator
- Current, 2019–Present A Phase 2 Open Label Study of Sacituzumab Govitecan (IMMU-132) in Subjects with Metastatic Solid Tumors
Gilead Sciences, 2019-0434
Principal Investigator
- Current, 2019–Present A Phase 2, Open-label, Multicenter, Study of an Immunotherapeutic Treatment, DPX-Survivac in combination with Low Dose Cyclophosphamide and Pembrolizumab, in Subjects with Selected Advanced and Recurrent Solid Tumours
IMV, 2019-0135
Collaborator (Fu, Siqing PI)
- Current, 2019–Present A Phase 1 Multiple-Dose Study to Evaluate the Safety and Tolerability of XmAb®22841 Monotherapy and in Combination with Pembrolizumab in Subjects with Selected Advanced Solid Tumors (DUET-4)
Xencor., 2019-0046
Collaborator (Pant, Shubham PI)
- Current, 2019–Present A Phase 1 Multiple-Dose Study to Evaluate the Safety and Tolerability of XmAb®23104 in Subjects with Selected Advanced Solid Tumors (DUET-3)
Xencor, 2019-0037
Collaborator (Pant, Shubham PI)
- Current, 2019–Present A Phase 1 Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Doses of pf-06939999 (prmt5-Inhibitor) in Participants With Advanced or Metastatic Non-small cell lung cancer, Head and Neck Squamous Cell Carcinoma, Esophageal Cancer, Endometrial Cancer, Cervical Cancer and Bladder cancer
Pfizer, 2019-0096
Collaborator (Rodon, Jordi PI)
- Current, 2019–Present A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors
Exelixis, 2019-0004 XL092
Collaborator (Subbiah, Vivek PI)
- Current, 2019–Present A Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 404, a Programmed Death-1 (PD-1) Antibody, in Patients With Advanced Solid Tumors
Amgen, 2019-0011
Co-Principal Investigator (Subbiah, Vivek PI)

- Current, 2019–Present A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)
Incyte Co, 2019-0323
Collaborator (Rodon, Jordi PI)
- Current, 2019–Present Phase I/II, First-In-Human, Multi-Part, Open-Label, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of DF1001 in Patients With Locally Advanced or Metastatic Solid Tumors, and Expansion in Selected Indications
Dragonfly Therapeutics, 2019-0506
Principal Investigator
- Current, 2018–Present FT500 as Monotherapy and in Combination with Immune Checkpoint Inhibitors in Subjects with Advanced Solid Tumors
Fate Therapeutics, Inc., 2018-0635
Collaborator (Hong, David S. PI)
- Current, 2018–Present A Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered Alone or in Combination with Atezolizumab to Subjects with Locally Advanced or Metastatic Solid Tumors
Exelixis, Inc, 2018-0963
Collaborator (Subbiah, Vivek PI)
- Current, 2018–Present A Phase I First Time in Human Open Label Study of GSK3745417 administered with and without Anticancer Agents in Participants with Advanced Solid Tumors
GlaxoSmithKline, 2018-0686
Co-Principal Investigator (Meric-Bernstam, Funda PI)
- Current, 2018–Present Phase 1, two-part, multicenter, non-randomized, open-label, multiple dose, first-in-human study of DS-1062a in subjects with advanced solid tumors
Daiichi Sankyo, 2018-0636
Collaborator
- Current, 2018–Present A Multicentre, Open-Label, Non-Randomised First in Human Study of NG-350A in Patients with Metastatic or Advanced Epithelial Tumours (FORTITUDE)
PsiOxus, 2018-0826
Co-Principal Investigator (Naing, Aung PI)
- Current, 2018–Present A Phase I/II, Open-Label, Multi-center Study of the Safety and Efficacy of KY1044 as Single Agent and in Combination with Anti-PD-L1 (Atezolizumab) in Adult Patients with Selected Advanced Malignancies
Kymab, 2018-0825
Co-Principal Investigator
- Current, 2018–Present A Phase 1 Dose-Escalation Study of FF-10832 for the Treatment of Advanced Solid Tumors
FujiFilm, 2018-0883
Collaborator (Janku, Filip PI)

- Current, 2018–Present A Phase 2 Study of the PARP Inhibitor Olaparib (AZD2281) in IDH1 and IDH2 mutant Advanced Solid Tumors
NCI-CTEP, NCI10129
Co-Principal Investigator (Rodon, Jordi PI)
- Current, 2018–Present A Phase 1b Study of ALRN-6924 in Combination with Paclitaxel in Wild-type TP53 Advanced or Metastatic Solid Tumors including Estrogen-Receptor Positive Breast Cancer
Investigator-Initiated Trial/ The University of Texas MD Anderson Cancer Center, 2018-0561
Principal Investigator
- Current, 2018–Present A Phase 1 Study of AZD8186 in Combination with Docetaxel in patients with PTEN mutated or PIK3CB mutated advanced solid tumors, potentially amenable to docetaxel
NCI-CTEP, NCI10131
Principal Investigator
- Current, 2018–Present A Phase 1a/1b Study of COM701 as Monotherapy and in Combination with an Anti-PD-1 Antibody in Subjects with Advanced Solid Tumors
Compugen Ltd, 2018-0891
Principal Investigator
- Current, 2018–Present A Phase II Basket Study of the Oral Selective pan-FGFR Inhibitor Debio 1347 in Subjects with Solid Tumors Harboring a Fusion of FGFR1, FGFR2 or FGFR3
DebioPharm, 2018-1000.
Collaborator (Meric-Bernstam, Meric PI)
- Current, 2018–Present A Phase I/II Open-label, Multi-center Study of the Safety and Efficacy of IMCnyeso, an HLA-A*0201-Restricted, NY-ESO-1- and LAGE-1A-specific Soluble T Cell Receptor and Anti-CD3 Bispecific Molecule, as a Single Agent in HLA-A*0201 Positive Patients with A
Immunomedics, 2018-0949
Co-Principal Investigator (Rodon Ahnert, Jordi PI)
- Current, 2018–Present A Phase 1/2 Single Arm Open-Label Clinical Trial of TC-210 T Cells in Patients with Advanced Mesothelin-Expressing Cancer
TCR2 Therapeutics, 2018-1094
Collaborator (Hong, David S. PI)
- Current, 2018–Present A Prospective Study Evaluating Complications and Clinical Response in Cancer Patients Treated with Anti-VEGF-Related Therapies, PA18-1070
Co-Principal Investigator (Naing, Aung PI)
- Current, 2018–Present A Phase I, Open-label, Dose Escalation and Dose Expansion Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumour Activity of IPN60090 as Single Agent and in Combination in Patients with Advanced Solid Tumours
Ipsen Biotech, 2018-0985
Co-Principal Investigator (Yap, Timothy Anthony PI)

- Current, 2018–Present An International Multi-Centre, Open-Label Study to Evaluate Safety, Tolerability, Biodistribution, Dosimetry and Preliminary Efficacy of ¹⁷⁷Lu-OPS201 for the Therapy of Somatostatin Receptor Positive Neuroendocrine Tumors (NETs)
Ipsen, 2018-0818
Collaborator (Rodon, Jordi PI)
- Current, 2018–Present A Phase I Study of SOR-C13 in Patients with Advanced Solid Tumors, 2018-0680
Collaborator (Fu, Siqing PI)
- Current, 2018–Present A multicenter open-label phase 1/1b study to evaluate the safety and preliminary efficacy of SO-C101 as monotherapy and in combination with pembrolizumab in patients with selected advanced/metastatic solid tumors
SOTIO, 2018-1005
Collaborator (Janku, Filip PI)
- Current, 2018–Present An Open-Label, Multicenter, Phase 1b/2 Study of Rebastinib (DCC-2036) in Combination with Carboplatin to Assess Safety, Tolerability, and Pharmacokinetics in Patients with Advanced or Metastatic Solid Tumors
Deciphera Pharmaceuticals, LLC., 2018-0954
Collaborator
- Current, 2018–Present An open label, Phase Ia/Ib dose finding study with BI 894999 orally administered once a day in patients with advanced malignancies with repeated administration in patients with clinical benefit
Boehringer Ingelheim, 2018-0682
Collaborator (Piha-Paul, Sarina PI)
- Current, 2018–Present A Phase 2 Study to Evaluate Safety and Anti-Tumor Activity of Avelumab in Combination with Talazoparib in Patients with BRCA or ATM Mutant Tumors
Pfizer, 2018-0256
Co-Principal Investigator (Yap, Timothy Anthony PI)
- Current, 2018–Present NCI10131: A Phase 1 Study of AZD8186 in Combination with Docetaxel in patients with PTEN mutated or PIK3CB mutated advanced solid tumors, potentially amenable to docetaxel, National Cancer Institute (NCI), NCI10131
Principal Investigator
- Current, 2016–Present Study of the Selective PI3K-Beta Inhibitor GSK2636771 in Combination with Pembrolizumab in Patients With Metastatic Melanoma and PTEN Loss, 2016-0774
Co-Principal Investigator (Tawbi H PI)
- Past, 2021–2023 A Phase 1b/2 Open-Label Study of the Efficacy and Safety of Etigilimab (MPH313) Administered in Combination with Nivolumab to Subjects with Locally Advanced or Metastatic Solid Tumors
Mereo BioPharma, 2021-0062
Principal Investigator
- Past, 2020–2023 A Phase 1, Multicenter, Open-label, Dose-Exploration and Dose-Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 650 in Subjects with Advanced Solid Tumors
Amgen, 2020-0080
Principal Investigator

- Past, 2020–2023 A Phase 1/2, Open-Label, Multicenter, Non-Randomized, Safety and Activity Study of HER2-Targeted Dual Switch Car-T Cells (BPX-603) in Subjects with Previously Treated Advanced HER2-Positive Solid Tumors
Bellicum Pharmaceuticals, Inc., 2020-0675
Principal Investigator
- Past, 2020–2023 A phase 1/2 feasibility, safety, and activity study of PSCA-specific chimeric antigen receptor engineered T cells (BPX-601) in subjects with previously treated advanced solid tumors
Bellicum Pharmaceuticals, Inc, 2020-0398
Principal Investigator
- Past, 2019 An Open-Label, Phase 1, First-In-Human, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Maximum Tolerated or Administered Dose, Pharmacokinetics, Pharmacodynamics and Tumor Response Profile of The Aryl Hydrocarbon Receptor Inhibitor
Bayer Healthcare Pharmaceuticals, Inc, 2019-0440
Principal Investigator
- Past, 2018 A Phase 1/2 Study of Galinpepimut-S in Combination with Pembrolizumab (MK-3475) in Patients with Selected Advanced Cancers
SELLAS Life Sciences Group, Inc., 2018-1140
Co-Principal Investigator (Fu, Siqing PI)
- Past, 2018 A Phase 1b/2, Open-label, Parallel Arm Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Oral Rucaparib in Combination with Other Anticancer Agents in Patients with a Solid Tumor
Clovis Oncology, Inc, 2018-1108
Co-Principal Investigator (Yap, Timothy Anthony PI)
- Past, 2018 A Phase 1a Study Evaluating the Safety, Tolerability, And Initial Efficacy of Recombinant Human Anti-Cluster Differentiation Antigen 47 (CD47) Monoclonal Antibody Injection (IBI188) In Patients with Advanced Malignant Tumors and Lymphomas
Innovent Biologics, 2018-1115
Collaborator (Fu, Siqing PI)
- Unknown A phase 1b/2 study of Milademetan in combination with Atezolizumab in Patients with advanced solid tumors with CDKN2A loss (MANTRA-4), Rain Oncology, Inc, 2023-0204
Co-Investigator
- Unknown, 2024–Present A phase 1/2, first-in-human, dose escalation and expansion study of BDC-3042 as a single agent and in combination with Pembrolizumab in patients with advanced malignancies, Bolt Biotherapeutics, Inc, 2023-0533
Principal Investigator

TEACHING AND TRAINING

**FORMAL TEACHING, UNDER- THROUGH
POST-GRADUATE**

- Jun 2023–Present Investigational Cancer Therapeutics Grand Rounds Presentations, Chair
The University of Texas MD Anderson Cancer Center
- Jun 2023–Present Chemotherapy and other systemic therapies in oncology/ GSBS Clinical
Perspective for a Basic Scientist (21-1301), Instructor
UT Graduate School of Biomedical Sciences;
- Nov 2022 Dose Selection and Biomarker Strategies for Phase I Drug Development/ Leading
Clinical Research Faculty Learning Series
The University of Texas MD Anderson Cancer Center
- Aug 2022–Present Serious Illness Conversation Guide Training, Trainer
The University of Texas MD Anderson Cancer Center
- Oct 2021 Monoclonal Antibodies/ Education for Patients Lunch and Learn
The University of Texas MD Anderson Cancer Center
- Mar 2020 Introduction to Clinical Research in Oncology (Course Director: Dr Elmer
Bernstam), Instructor
University of Texas Health Graduate School of Biomedical Informatics;
- Dec 2019 Understanding Clinical Trials/ Education for Patients Lunch and Learn
The University of Texas MD Anderson Cancer Center
- Nov 2019 Understanding Molecular Profiling/ Education for Advance Practice Providers
The University of Texas MD Anderson Cancer Center
- Feb 2019 Managing Immune-Related Toxicities in Clinical Trials/ Education for Nursing,
Data, and, Research Study Coordinators
The University of Texas MD Anderson Cancer Center
- 2018–Present Journal Club Presentations/ Investigational Cancer Therapeutics Fellowship
The University of Texas MD Anderson Cancer Center

**LAB OR OTHER RESEARCH SUPERVISION
AND TRAINING**

- Advisory Committees (Advisory Committee Member), The University of Texas
MD Anderson Cancer Center
Seyed Saeed Pairawan
- 2021–Present Direct Supervision - Postdoctoral Research Fellows (Supervisor), The University
of Texas MD Anderson Cancer Center
2021–Present, Burak Uzunparmak
- 2021 Supervision (Supervisor), University Hospital, LMU Munich
2021, Anca Chelariu-Raicu
- 2020–2022 Direct Supervision - Undergraduate and Allied Health Students (Supervisor), The
University of Texas MD Anderson Cancer Center
2020–2022, Advance Nurse Practitioners

FORMAL TEACHING OF PEERS

- Nov 04, 2024 Serious Illness Conversation Guide Training, 3
Virtual meeting
The University of Texas MD Anderson Cancer Center
- Oct 07, 2024–Present Inpatient Policies, 45
ICT Grand Rounds
Virtual

- The University of Texas MD Anderson Cancer Center
- May 10, 2019 Challenges in Translational Cancer Research
Updates in Oncology Conference; Iasi, Romania
- May 10, 2019 Translational Cancer Research: from bench to bedside and back
Updates in Oncology Conference; Iasi, Romania
- May 10, 2019 Translational Research in Breast Cancer
Updates in Oncology Conference; Iasi, Romania

PRESENTATIONS & TALKS

LOCAL

- Sep 25, 2024 Bedside to Bench
MDACC Annual Cancer Network Summit Meeting
Invited talk/seminar
The University of Texas MD Anderson Cancer Center
- May 2022 Emerging Therapeutics in Treatment of Advanced Breast Cancer
Peer-reviewed conference presentation
Advanced Breast Cancer Conference; Houston, TX
- Feb 2020 Phase I Aspect of Advanced Breast Cancer
Peer-reviewed conference presentation
Advanced Breast Cancer Conference; Houston, TX

NATIONAL

- Jun 02, 2025 Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology -
Oral Abstract
2025 ASCO Annual Meeting
Peer-reviewed conference presentation (Presenter)
American Society of Clinical Oncology (ASCO); Chicago, IL
- Apr 29, 2025 First-in-Human Phase I Clinical Trials 2
AACR Annual Meeting 2025
Poster presentation (Presenter)
AACR Annual Meeting 2025; Chicago, IL
- Mar 16, 2025 The PYNACLE Phase 2 trial assessing rezatapopt (PC14586), a selective p53
reactivator, in patients with locally advanced or metastatic solid tumors
(including ovarian and endometrial cancers) harboring a TP53 Y220C mutation
SGO Annual Meeting on Women's Cancer
Poster presentation (Presenter)
Society of Gynecologic Oncology; Seattle, Washington
- Jan 23, 2025 Cancers of the Esophagus and Stomach and Other Gastrointestinal Cancers
ASCO Gastrointestinal Cancers Symposium
Poster presentation (Presenter)
American Society of Clinical Oncology (ASCO); San Francisco, CA
- Jan 23, 2025 Cancers of the Esophagus and Stomach and Other Gastrointestinal Cancers
ASCO Gastrointestinal Cancers Symposium
Poster presentation (Presenter)
American Society of Clinical Oncology (ASCO); San Francisco, CA
- Apr 2023 Preliminary analysis of pharmacokinetic (PK) and target engagement biomarkers
from a first in human phase 1 study of immunomodulatory aryl hydrocarbon
receptor (AhR) inhibitor BAY2416964
Peer-reviewed conference presentation (Presenter)
AACR Annual Meeting 2023; Orlando, FL

- Apr 2023 A phase I/II trial investigating safety and efficacy of autologous TAC01-HER2 in relapsed or refractory solid tumors
Peer-reviewed conference presentation (Presenter)
AACR Annual Meeting 2023; Orlando, FL
- Mar 2023 Targeting "non-druggable" targets in oncology
Peer-reviewed conference presentation (Presenter)
Banner Health MD Anderson Cancer Center 5th Annual Innovations in Oncology Symposium; Phoenix, AZ
- Mar 2023 CAR-T and NK cell therapies in solid tumors
Peer-reviewed conference presentation (Presenter)
Inaugural Stem Cell Transplant and Cellular Therapy Symposium; Phoenix, AZ
- Jul 2022 HER2 Targeting Agents in Gynecological Malignancies
Peer-reviewed conference presentation (Presenter)
NRG Oncology Summer Meeting; Chicago, IL
- Apr 2022 A phase I/II trial investigating safety and efficacy of autologous TAC T cells targeting HER2 in relapsed or refractory solid tumors (TACTIC-2)
Peer-reviewed conference presentation (Presenter)
AACR Annual Meeting 2022; New Orleans, LA
- Apr 2022 A phase 2 study of the MDM2 inhibitor milademetan in patients with TP53-wild type and MDM2-amplified advanced or metastatic solid tumors (MANTRA-2)
Peer-reviewed conference presentation (Presenter)
AACR Annual Meeting 2022; New Orleans, LA
- Nov 2021 COM902 (Anti-TIGIT Antibody) Monotherapy – Preliminary Evaluation Of Safety, Tolerability, Pharmacokinetics And Receptor Occupancy In Patients With Advanced Solid Tumors (NCT04354246)
Peer-reviewed conference presentation (Presenter)
SITC Annual Meeting 2021; Virtual
- Nov 2021 COM701 in combination with BMS-986207 (Anti-TIGIT antibody) and nivolumab – preliminary results of safety, tolerability and pharmacokinetics in patients with advanced solid tumors (NCT04570839)
Peer-reviewed conference presentation (Presenter)
SITC Annual Meeting 2021; Virtual
- Apr 2021 HER2 Targeted Immunotherapy
Peer-reviewed conference presentation (Presenter)
Cholangiocarcinoma Foundation Annual Conference 2021; Virtual
- Dec 2020 Phase 1/2 study of a novel HER2 targeting TLR7/8 immune-stimulating antibody conjugate (ISAC), BDC-1001, as a single agent and in combination with an immune checkpoint inhibitor in patients with advanced HER2-expressing solid tumors
Peer-reviewed conference presentation (Presenter)
San Antonio Breast Cancer Symposium (SABCS); San Antonio, TX
- Oct 2020 Handling TIGIT in the Clinic, Building Clinical Trial Strategy, Managing Toxicity, and Optimizing Patient Selection to Maximize Clinical Trial Success
Peer-reviewed conference presentation (Presenter)
TIGIT Therapies Digital Consortium; Virtual
- Apr 2020 A phase 1b study of nivolumab in patients with autoimmune disorders and advanced malignancies (AIM-NIVO)
Peer-reviewed conference presentation (Presenter)
AACR Annual Meeting 2020; Virtual
- Nov 2019 Phase 1 study of COM701 monotherapy and in combination with nivolumab in patients with advanced solid tumors

- Peer-reviewed conference presentation (Presenter)
SITC Annual Meeting 2019; Washington, DC
- Nov 2019 Phase 1 study of the safety, tolerability and preliminary anti-tumor activity of COM701 monotherapy in patients with advanced solid tumors
Peer-reviewed conference presentation (Presenter)
SITC Annual Meeting 2019; Washington, DC
- Nov 2019 A Phase 1 Dose Escalation Study to Evaluate the Safety and Tolerability of Evofosfamide in Combination with Ipilimumab in Advanced Solid Malignancies
Peer-reviewed conference presentation (Presenter)
SITC Annual Meeting 2019; Washington, DC
- Oct 2017 Targeting HER2 (ERBB2) amplification identified by next-generation sequencing (NGS) in patients with advanced or metastatic solid tumors
Peer-reviewed conference presentation (Presenter)
AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference; Philadelphia, PA
- Apr 2015 Circulating cell-free tumor DNA (cfDNA) analysis of 50-genes by next-generation sequencing (NGS) in the prospective MOSCATO trial
Peer-reviewed conference presentation (Presenter)
AACR Annual Meeting 2015; Philadelphia, PA
- Apr 2014 Molecular screening for cancer treatment optimization (MOSCATO 01): a prospective molecular triage trial; Interim analysis of 420 patients.
Peer-reviewed conference presentation (Presenter)
AACR Annual Meeting 2014; San Diego, CA

INTERNATIONAL

- Jun 2023 Initial results from a first-in-human, phase I study of immunomodulatory aryl hydrocarbon receptor (AhR) inhibitor BAY2416964 in patients with advanced solid tumors
Peer-reviewed conference presentation (Presenter)
ASCO Annual Meeting 2023; Chicago, IL
- Jun 2023 TROPiCS-03: A phase 2 basket study of sacituzumab govitecan (SG) in patients (pts) with metastatic solid tumors—Early analysis in pts with advanced/metastatic endometrial cancer (EC)
Peer-reviewed conference presentation (Presenter)
ASCO Annual Meeting 2023; Chicago, IL
- Jun 2023 Molecular landscape and survival outcomes on early phase clinical trials in sporadic young onset colorectal cancer
Peer-reviewed conference presentation (Presenter)
ASCO Annual Meeting 2023; Chicago, IL
- Jun 2023 A phase 1/2 study of a first-in-human immune-stimulating antibody conjugate (ISAC) BDC-1001 in patients with advanced HER2-expressing solid tumors
Peer-reviewed conference presentation (Presenter)
ASCO Annual Meeting 2023; Chicago, IL
- Jun 2023 Preliminary antitumor activity of the combination of COM701 + BMS-986207 + nivolumab in patients with recurrent, metastatic MSS endometrial cancer
Peer-reviewed conference presentation (Presenter)
ASCO Annual Meeting 2023; Chicago, IL
- Jun 2023 Predictors of survival outcomes in patients (pts) with advanced solid tumors treated with cellular therapies in early clinical trials
Peer-reviewed conference presentation (Presenter)
ASCO Annual Meeting 2023; Chicago, IL

- Jun 2023 A phase I/II trial investigating safety and efficacy of autologous TAC01-HER2 in relapsed or refractory solid tumors
Peer-reviewed conference presentation (Presenter)
ASCO Annual Meeting 2023; Chicago, IL
- Jun 2023 Baseline symptom, health status, and health utilities in patients in early-phase clinical trials combining immune checkpoint blockade with other anticancer therapies
Peer-reviewed conference presentation (Presenter)
ASCO Annual Meeting 2023; Chicago, IL
- Oct 2022 Targeting p53 in patients with metastatic cancer and Li-Fraumeni Syndrome
Peer-reviewed conference presentation (Presenter)
6th International LFS Association Symposium; Bethesda, MD
- Jun 2022 Meet the Professor: An Interview with a Legend in Drug Development
Peer-reviewed conference presentation (Presenter)
ASCO Annual Meeting 2022; Chicago, IL
- Jun 2022 A phase 2 study of the MDM2 inhibitor milademetan in patients with TP53-wild type and MDM2-amplified advanced or metastatic solid tumors (MANTRA-2)
Peer-reviewed conference presentation (Presenter)
ASCO Annual Meeting 2022; Chicago, IL
- Jun 2022 Phase I/II study of the selective PI3K β inhibitor GSK2636771 in combination with pembrolizumab in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and PTEN loss
Peer-reviewed conference presentation (Presenter)
ASCO Annual Meeting 2022; Chicago, IL
- Jun 2022 First-in-human study of PC14586, a small molecule structural corrector of Y220C mutant p53, in patients with advanced solid tumors harboring a TP53 Y220C mutation
Peer-reviewed conference presentation (Presenter)
ASCO Annual Meeting 2022; Chicago, IL
- Jun 2021 A phase 1b study of nivolumab in patients with autoimmune disorders and advanced malignancies (AIM-NIVO)
Peer-reviewed conference presentation (Presenter)
ASCO Annual Meeting 2021; Virtual
- Jun 2021 Phase 1/2 study of eprenetapopt (APR-246) in combination with pembrolizumab in patients with solid tumor malignancies.
Peer-reviewed conference presentation (Presenter)
ASCO Annual Meeting 2021; Virtual
- Jun 2021 Phase 1b/2 SEASTAR trial: Safety, pharmacokinetics, and preliminary efficacy of the poly(ADP)-ribose polymerase (PARP) inhibitor rucaparib and angiogenesis inhibitor lucitanib in patients with advanced solid tumors
Peer-reviewed conference presentation (Presenter)
ASCO Annual Meeting 2021; Virtual
- Jun 2020 Phase I study of TT-00420, a multiple kinase inhibitor, in patients with triple-negative breast cancers and other advanced solid tumors
Peer-reviewed conference presentation (Presenter)
ASCO Annual Meeting 2020; Virtual
- Jun 2020 A phase Ib study of nivolumab in patients with autoimmune disorders and advanced malignancies (AIM-NIVO)
Peer-reviewed conference presentation (Presenter)
ASCO Annual Meeting 2020; Virtual
- Oct 2019 The combination of MEK and MDM2 inhibitors demonstrates promising antitumor efficacy in MAPK-altered patient-derived thyroid and colorectal

- cancer models
Peer-reviewed conference presentation (Presenter)
AACR-NCI-EORTC International Conference on Molecular Targets and Cancer;
Boston, MA
- Jun 2019 A multicenter, open label, first-in-human study of an oncolytic viral vector expressing an agonistic anti-CD40 antibody (NG-350A) in patients with epithelial tumors (FORTITUDE)
Peer-reviewed conference presentation (Presenter)
ASCO Annual Meeting 2019; Chicago, IL
- Jun 2019 Phase I trial of IACS-010759 (IACS), a potent, selective inhibitor of complex I of the mitochondrial electron transport chain, in patients (pts) with advanced solid tumors
Peer-reviewed conference presentation (Presenter)
ASCO Annual Meeting 2019; Chicago, IL
- Jun 2017 Pathogenic variants in DNA damage response (DDR) genes in patients with advanced solid tumors
Peer-reviewed conference presentation (Presenter)
ASCO Annual Meeting 2017; Chicago, IL
- Mar 2014 Phase I study of temsirolimus in combination with cetuximab in patients with advanced solid tumors
Peer-reviewed conference presentation (Presenter)
12th International Congress on Targeted Anticancer Therapies (TAT);
Washington, DC
- Jun 2013 Effects of abiraterone acetate and enzalutamide on muscle and adipose mass in men with metastatic castration-resistant prostate cancer (mCRPC)
Peer-reviewed conference presentation (Presenter)
ASCO Annual Meeting 2013; Chicago, IL
- Sep 2012 Abiraterone in patients with metastatic castration-resistant prostate cancer progressing after docetaxel and MDV3100: A multicentre study
Peer-reviewed conference presentation (Presenter)
37th ESMO Multidisciplinary Congress 2012; Vienna, Austria
- Jun 2012 Abiraterone in patients with metastatic castration-resistant prostate cancer progressing after docetaxel and MDV3100
Peer-reviewed conference presentation (Presenter)
ASCO Annual Meeting 2012; Chicago, IL
- Oct 2010 Embryonal rhabdomyosarcoma of the uterine cervix: a case report and review of the literature
Peer-reviewed conference presentation (Presenter)
13th Biennial Meeting of the International Gynecologic Society; Prague, Czechia
- Sep 2010 Where did my central line go? The pinch-off syndrome
Peer-reviewed conference presentation (Presenter)
8th Congress of the Balkan Union of Oncology (BUON); Sibiu, Romania
- Jul 2009 Efficacy of endoscopic treatment in chronic pancreatitis assessed by Izbicki Score.
Peer-reviewed conference presentation (Presenter)
41st European Pancreatic Club (EPC) Meeting; Szeged, Hungary
- Dec 2007 Prevention of infantile obesity
Peer-reviewed conference presentation (Presenter)
9th National Congress of Medical Students; Bucharest, Romania
- May 2007 Endoscopic treatment of colorectal obstruction with self-expandable metal stents

- Peer-reviewed conference presentation (Presenter)
15th International Student Scientific Conference (ISSC); Gdansk, Poland
- Mar 2005 ADHD: Current Treatment and Controversies
Peer-reviewed conference presentation (Presenter)
7th International Medicalis Conference for students and young doctors; Cluj-Napoca, Romania

ORGANIZING CONFERENCES/CHAIRING SESSIONS

NATIONAL

- Apr 2023 AACR Annual Meeting Clinical Trials Committee 2023
Member
- Apr 2023 Novel Immunotherapy Combination Clinical Trials
Session Chair
AACR Annual Meeting 2023; Orlando, FL
- Dec 2022 IOTOX Clinical Education Symposium
Moderator
Rare immune-related adverse events session;

PUBLICATIONS

JOURNAL ARTICLES - ORIGINAL RESEARCH

- Uzunparmak B, Haymaker C, Raso G, Masciari S, Wang L, Lin H, Gorur A, Kirby B, Cimo AM, Kennon A, Ding Q, Urschel G, Yuan Y, Feng G, Rizvi Y, Hussain A, Zhu C, Kim P, Abbadessa G, Subbiah V, Yap TA, Rodon J, Piha-Paul SA, Meric-Bernstam F, **Dumbrava E**. HER2-low expression in patients with advanced or metastatic solid tumors. *Annals of Oncology*. Unknown status.
- Gouda, MA, Gonugunta, A, **Ileana Dumbrava, EE**, Yap, TA, Rodon Ahnert, J, Piha-Paul, SA, Pohlmann, PR, Damodaran, S, Murthy, RK, Valero, V, Mouabbi, JA, Tripathy, D, Sahin, AA, Chen, H, Meric-Bernstam, F. Human Epidermal Growth Factor Receptor 2 Loss following Treatment with Trastuzumab Deruxtecan in Patients with Metastatic Breast Cancer. *Clinical Cancer Research*. 2025 Apr 01; 31(7):1268-1274. PMID: 39841861 <https://doi.org/10.1158/1078-0432.CCR-24-3468>.
- Michel, L, Jimeno, A, Sukari, A, Beck, JT, Chiu, J, Ahern, E, Hilton, J, Even, C, Zanetta, S, Mekan, S, Patel, J, Wu, T, **Ileana Dumbrava, EE**. Sacituzumab Govitecan in Patients with Relapsed/Refractory Advanced Head and Neck Squamous Cell Carcinoma. *Clinical cancer research : an official journal of the American Association for Cancer Research*. 2025 Mar 03; 31(5):832-838. PMID: 39665770 <https://doi.org/10.1158/1078-0432.CCR-24-2523>.
- Stein, MN, **Ileana Dumbrava, EE**, Teply, BA, Gergis, U, Guterrez, ME, Reshef, R, Subudhi, SK, Jacquemont, C, Senesac, JH, Bayle, JH, Scripture, CD, Chatwal, M, Bilen, MA, Stadler, WM, Becerra, CR. PSCA-targeted BPX-601 CAR T cells with pharmacological activation by rimiducid in metastatic pancreatic and prostate cancer. *Nature communications*. 2024 Dec 01; 15(1) PMID: 39737899 PMCID: PMC11685978.
- Tao, DL, Nardo, M, Leung, CH, Lin, HY, Kang, L, Le, H, **Ileana Dumbrava, EE**, Hong, DS. Obesity and Outcomes in Adoptive Cellular Therapy in Solid Tumors. *JAMA Network Open*. 2024 Nov 25; 7(11) PMID: 39585697 PMCID: PMC11589797.
- Holla, V, Kahle, M, Kim, SH, Ronaghy, A, Yang, RK, Patel, KP, Routbort, MJ, Overman, MJ, **Ileana Dumbrava, EE**, Mills Shaw, KR, Karp, DD, Meric-Bernstam, F. Genomic Alterations in DNA Mismatch Repair Genes Across Different Cancer Types. *JCO Precision Oncology*. 2024 Nov 01; 8 PMID: 39576951 PMCID: PMC11825140.
- Chang, JY, Xu, X, Shroff, G, Comeaux, NI, Li, W, Rodon Ahnert, J, Karp, DD, **Ileana Dumbrava, EE**, Verma, V, Chen, A, Welsh, J, Hong, DS. Phase I/II study of BMS-986156 with ipilimumab or nivolumab with or without stereotactic ablative radiotherapy in patients with advanced solid malignancies. *Journal for immunotherapy of cancer*. 2024 Oct 09; 12(10) PMID: 39384194 PMCID: PMC11474930.
- Mohamed, YI, Lee, SS, Demir, T, Chamseddine, SM, Hu, ZI, Xiao, L, Elsayes, KM, Morris, JS, Wolff, RA, Hiattia, R, Qayyum, A, Rashid, A, Duda, DG, Yao, JC, Lapelusa, M, Koay, EJ, Mahvash, A, Al Azzam, A, **Ileana Dumbrava, EE**, Hassan, MM, Amin, HM,

- Kaseb, A. Circulating tumor DNA (ctDNA) as a biomarker of response to therapy in advanced Hepatocellular carcinoma treated with Nivolumab. *Cancer Biomarkers*. 2024 Sep 19; 41(1):83-91. PMID: 39269823 PMCID: PMC11491993.
9. Santin AD, Corr BR, Spira A, Willmott L, Butrynski J, Tse KY, Patel J, Mekan S, Wu T, Lin KW, Kuo P, **Dumbrava EE**. Efficacy and Safety of Sacituzumab Govitecan in Patients With Advanced Solid Tumors (TROPiCS-03): Analysis in Patients With Advanced Endometrial Cancer. *J Clin Oncol*. 2024 Jul 31; 42(29):JCO2302767. PMID: 39083724 PMCID: PMC11458108.
 10. Tang, C, Hartley, G, Couillault, CA, Yuan, Y, Lin, Y, Nicholas, C, Srinivasamani, A, Dai, J, **Ileana Dumbrava, EE**, Fu, S, Karp, DD, Naing, A, Piha-Paul, SA, Rodon Ahnert, J, Pant, S, Subbiah, V, Yap, T, Tsimberidou, AM, Guerrero, PA, Dhebat, S, Proia, T, Curran, M, Hong, DS. Preclinical study and parallel phase II trial evaluating antisense STAT3 oligonucleotide and checkpoint blockade for advanced pancreatic, non-small cell lung cancer and mismatch repair-deficient colorectal cancer. *BMJ Oncology*. 2024 Jul 30; 3(1) PMID: 39886125 PMCID: PMC11347683.
 11. Gouda, MA, Shunyakova, J, Naing, A, **Ileana Dumbrava, EE**, Hong, DS, Yuan, Y, Yang, P, Myers, AL, Liang, Y, Peng, J, Karp, DD, Tsimberidou, AM, Rodon Ahnert, J, Yap, TA, Piha-Paul, SA, Meric-Bernstam, F, Fu, S. A phase I study of TAK-659 and paclitaxel in patients with taxane-refractory advanced solid tumors. *ESMO Open*. 2024 Jun 01; 9(6) PMID: 38914452 PMCID: PMC11258623.
 12. DiPeri TP, Evans KW, Wang B, Zhao M, Akcakanat A, Raso MG, Rizvi YQ, Zheng X, Korkut A, Varadarajan K, Uzunparmak B, **Dumbrava EE**, Pant S, Ajani JA, Pohlmann PR, Jensen VB, Javle M, Rodon J, Meric-Bernstam F. Co-clinical Trial of Novel Bispecific Anti-HER2 Antibody Zanidatamab in Patient-Derived Xenografts. *Cancer Discov*. 2024 May 01; 14(5):828-845. PMID: 38358339 PMCID: PMC11064988.
 13. Piha-Paul SA, Xu B, **Dumbrava EE**, Fu S, Karp DD, Meric-Bernstam F, Hong DS, Rodon JA, Tsimberidou AM, Raghav K, Ajani JA, Conley AP, Mott F, Fan Y, Fan J, Peng P, Wang H, Ni S, Sun C, Qiang X, Levin WJ, Ngo B, Ru QC, Wu F, Javle MM. First-In-Human Phase I Study of Tinengotinib (TT-00420), a Multiple Kinase Inhibitor, as a Single Agent in Patients With Advanced Solid Tumors. *Oncologist*. 2024 Apr 04; 29(4):e514-e525. PMID: 38297981 PMCID: PMC10994248.
 14. Subbiah V, Coleman N, Piha-Paul SA, Tsimberidou AM, Janku F, Rodon J, Pant S, Dumbrava EE, Fu S, Hong DS, Zhang S, Sun M, Jiang Y, Roszik J, Song J, Yuan Y, Meric-Bernstam F, Naing A. Phase I Study of mTORC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with mTOR/AKT/PI3K Pathway Alterations and Advanced Solid Malignancies. *Cancer Res Commun*. 2024 Feb 12; 4(2):378-387. PMID: 38126764 PMCID: PMC10860536.
 15. Knisely A, Ahmed J, Stephen B, Piha-Paul SA, Karp D, Zarifa A, Fu S, Hong DS, Rodon Ahnert J, Yap TA, Tsimberidou AM, Alshawa A, **Dumbrava EE**, Yang Y, Song J, Meric-Bernstam F, Jazaeri AA, Naing A. Phase 1/2 trial of avelumab combined with utomilumab (4-1BB agonist), PF-04518600 (OX40 agonist), or radiotherapy in patients with advanced gynecologic malignancies. *Cancer*. 2024 Feb 01; 130(3):400-409. PMID: 37864520 PMCID: PMC10841432.
 16. Nowlen, CJ, Daniels, MS, Uzunparmak, B, **Ileana Dumbrava, EE**, Yuan, Y, Patel, KP, Rayes, N, Harkenrider, J, Wathoo, C, Veazie, J, Luna, KA, Wang, W, Horombe, C, Javle, M, Rodon Ahnert, J, Yap, TA, Arun, BK, Lu, KH, Meric-Bernstam, F. Limited Independent Follow-Up with Germline Testing of Variants Detected in BRCA1 and BRCA2 by Tumor-Only Sequencing. *Journal of Immunotherapy and Precision Oncology*. 2024 Feb 01; 7(1):7-17. PMID: 38327755 PMCID: PMC10846638.
 17. DiPeri TP, Evans KW, Raso MG, Zhao M, Rizvi YQ, Zheng X, Wang B, Kirby BP, Kong K, Kahle M, Yap TA, **Dumbrava EE**, Ajani JA, Fu S, Keyomarsi K, Meric-Bernstam F. Adavosertib Enhances Antitumor Activity of Trastuzumab Deruxtecan in HER2-Expressing Cancers. *Clin Cancer Res*. 2023 Nov 01; 29(21):4385-4398. PMID: 37279095 PMCID: PMC10618648.
 18. Uzunparmak B, Haymaker C, Raso G, Masciari S, Wang L, Lin H, Gorur A, Kirby B, Cimo AM, Kennon A, Ding Q, Urschel G, Yuan Y, Feng G, Rizvi Y, Hussain A, Zhu C, Kim P, Abbadessa G, Subbiah V, Yap TA, Rodon J, Piha-Paul SA, Meric-Bernstam F, **Dumbrava EE**. HER2-low expression in patients with advanced or metastatic solid tumors. *Ann Oncol*. 2023 Nov; 34(11):1035-1046. PMID: 37619847 <https://doi.org/10.1016/j.annonc.2023.08.005>.
 19. Zhao M, DiPeri TP, Raso MG, Zheng X, Rizvi YQ, Evans KW, Yang F, Akcakanat A, Roberto Estecio M, Tripathy D, **Dumbrava EE**, Damodaran S, Meric-Bernstam F. Epigenetically upregulating TROP2 and SLFN11 enhances therapeutic efficacy of TROP2 antibody drug conjugate sacituzumab govitecan. *NPJ Breast Cancer*. 2023 Nov; 9(1):66.
 20. Zhao M, DiPeri TP, Raso MG, Zheng X, Rizvi YQ, Evans KW, Yang F, Akcakanat A, Roberto Estecio M, Tripathy D, **Dumbrava EE**, Damodaran S, Meric-Bernstam F. Epigenetically upregulating TROP2 and SLFN11 enhances therapeutic efficacy of TROP2 antibody drug conjugate sacituzumab govitecan. *NPJ Breast Cancer*. 2023 Aug 11; 9(1):66. PMID: 37567892 PMCID: PMC10421911.
 21. DiPeri TP, Kong K, Varadarajan K, Karp DD, Ajani JA, Pant S, Press MF, Piha-Paul SA, **Dumbrava EE**, Meric-Bernstam F. Discordance of HER2 Expression and/or Amplification on Repeat Testing. *Mol Cancer Ther*. 2023 Aug 01; 22(8):976-984. PMID: 37339271 PMCID: PMC10751575.

22. DiPeri TP, Kong K, Varadarajan K, Karp DD, Ajani JA, Pant S, Press MF, Piha-Paul SA, **Dumbrava EE**, Meric-Bernstam F. Discordance of HER2 Expression and/or Amplification on Repeat Testing. *Mol Cancer Ther.* 2023 Aug; 22(8):976-984.
23. Nelson BE, Saleem S, Damodaran S, Somaiah N, Piha-Paul S, Moore JA, Yilmaz B, Ogbonna D, Karp DD, **Dumbrava E**, Tsimberidou AM, Hong DS, Rodon Ahnert J, Milton DR, Zheng X, Booser DJ, Ibrahim NK, Conley AP, Bhosale P, Rojas Hernandez CM, Tripathy D, Naing A, Meric-Bernstam F. Phase 1b study of combined selinexor and eribulin for the treatment of advanced solid tumors and triple-negative breast cancer. *Cancer.* 2023 Jul; 129(14):2201-2213.
24. DiPeri TP, Evans KW, Raso MG, Zhao M, Rizvi YQ, Zheng X, Wang B, Kirby BP, Kong K, Kahle M, Yap TA, **Ileana Dumbrava EE**, Ajani JA, Fu S, Keyomarsi K, Meric-Bernstam F. Adavosertib Enhances Antitumor Activity of Trastuzumab Deruxtecan in HER2-Expressing Cancers. *Clin Cancer Res.* 2023 Jun.
25. Son J, Lin HY, Fu S, Biter AB, **Dumbrava EE**, Karp DD, Naing A, Pant S, Piha-Paul SA, Rodon J, Subbiah V, Tsimberidou AM, Yap TA, Frumovitz MM, Jazaeri AA, Ramirez PT, Westin SN, Yuan Y, Meric-Bernstam F, Hong DS. Predictors of Oncologic Outcome in Patients Receiving Phase I Investigational Therapy for Recurrent or Metastatic Cervical Cancer. *J Immunother Precis Oncol.* 2023 Feb; 6(1):10-18. PMID: 36751659 PMCID: PMC9888522.
26. Yap TA, Daver N, Mahendra M, Zhang J, Kamiya-Matsuoka C, Meric-Bernstam F, Kantarjian HM, Ravandi F, Collins ME, Francesco MED, **Dumbrava EE**, Fu S, Gao S, Gay JP, Gera S, Han J, Hong DS, Jabbour EJ, Ju Z, Karp DD, Lodi A, Molina JR, Baran N, Naing A, Ohanian M, Pant S, Pemmaraju N, Bose P, Piha-Paul SA, Rodon J, Salguero C, Sasaki K, Singh AK, Subbiah V, Tsimberidou AM, Xu QA, Yilmaz M, Zhang Q, Li Y, Bristow CA, Bhattacharjee MB, Tiziani S, Heffernan TP, Vellano CP, Jones P, Heijnen CJ, Kavelaars A, Marszalek JR, Konopleva M. Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials. *Nat Med.* 2023 Jan; 29(1):115-126. PMID: 36658425.
27. Fu S, Yao S, Yuan Y, Previs RA, Elias AD, Carvajal RD, George TJ, Yuan Y, Yu L, Westin SN, Xing Y, **Dumbrava EE**, Karp DD, Piha-Paul SA, Tsimberidou AM, Ahnert JR, Takebe N, Lu K, Keyomarsi K, Meric-Bernstam F. Multicenter Phase II Trial of the WEE1 Inhibitor Adavosertib in Refractory Solid Tumors Harboring CCNE1 Amplification. *J Clin Oncol.* E-pub ahead of print: 2022 Dec; PMID: 36469840.
28. Park H, Shapiro GI, Gao X, Mahipal A, Starr J, Furqan M, Singh P, Ahrorov A, Gandhi L, Ghosh A, Hickman D, Gallacher PD, Wennborg A, Attar EC, Awad MM, Das S, **Dumbrava EE**. Phase Ib study of eprenetapopt (APR-246) in combination with pembrolizumab in patients with advanced or metastatic solid tumors. *ESMO Open.* 2022 Oct; 7(5):100573. PMID: 36084396 PMCID: PMC9588880.
29. Barber FD, Campbell E, Yamamura Y, Patterson CJ, Hartnett AC, Kinahan H, Miller VA, Brink AL, Poullard A, Urschel GE, Brantley A, Cepeda IG, Goswami P, Charles S, Philip S, Bresser S, Musekiwa-Adjei S, Perez N, Le H, Phillips P, Subbiah V, Meric-Bernstam F, **Dumbrava EE**. Management of Adverse Events in Early Clinical Trials by Advanced Practice Providers in the Outpatient Setting: The University of Texas MD Anderson Cancer Center Experience. *J Adv Pract Oncol.* 2022 Sep; 13(7):664-672. PMID: 36199491 PMCID: PMC9514129.
30. Mendoza TR, Hong DS, Peterson CB, Stephen B, **Dumbrava E**, Pant S, Tsimberidou AM, Yap TA, Sheshadri A, Altan M, George G, Castillo L, Rodriguez E, Gong J, Subbiah V, Janku F, Fu S, Piha-Paul SA, Ahnert JR, Karp DD, Cleeland C, Meric-Bernstam F, Naing A. Patient-reported symptom burden in patients with rare cancers receiving pembrolizumab in a phase II Clinical Trial. *Sci Rep.* 2022 Aug; 12(1):14367. PMID: 35999229 PMCID: PMC9399082.
31. Yap TA, Hamilton E, Bauer T, **Dumbrava EE**, Jeselsohn R, Enke A, Hurley S, Lin KK, Habeck J, Giordano H, Shapiro GI. Phase Ib SEASTAR Study: Combining Rucaparib and Sacituzumab Govitecan in Patients with Cancer With or Without Mutations in Homologous Recombination Repair Genes. *JCO Precis Oncol.* 2022 Feb; PMID: 35138920 PMCID: P8865521.
32. Pairawan S, Akcakanat A, Kopetz S, Tapia C, Zheng X, Chen H, Ha MJ, Rizvi Y, Holla V, Wang J, Evans KW, Zhao M, Busaidy N, Fang B, Roth JA, **Dumbrava EI**, Meric-Bernstam F. Combined MEK/MDM2 inhibition demonstrates antitumor efficacy in TP53 wild-type thyroid and colorectal cancers with MAPK alterations. *Sci Rep.* 2022 Jan; 12(1):1248.
33. Pairawan S, Akcakanat A, Kopetz S, Tapia C, Zheng X, Chen H, Ha MJ, Rizvi Y, Holla V, Wang J, Evans KW, Zhao M, Busaidy N, Fang B, Roth JA, **Dumbrava EE**, Meric-Bernstam F. Combined MEK/MDM2 inhibition demonstrates antitumor efficacy in TP53 wild-type thyroid and colorectal cancers with MAPK alterations. *Sci Rep.* 2022 Jan; 12(1):1248. PMID: 35075200 PMCID: PMC8786858.
34. Hong DS, Butler MO, Pachynski RK, Sullivan R, Kebriaei P, Boross-Harmer S, Ghobadi A, Frigault MJ, **Dumbrava EE**, Sauer A, Brophy F, Navenot JM, Fayngerts S, Wolchinsky Z, Broad R, Batrakou DG, Wang R, Solis LM, Duose DY, Sanderson JP, Gerry AB, Marks D, Bai J, Norry E, Fracasso PM. Phase 1 Clinical Trial Evaluating the Safety and Anti-Tumor Activity of ADP-A2M10 SPEAR T-Cells in Patients With MAGE-A10+ Head and Neck, Melanoma, or Urothelial Tumors. *Front Oncol.* 2022; 12:818679. PMID: 35372008 PMCID: PMC8972123.

35. Greenbaum U, **Dumbrava EE**, Biter AB, Haymaker CL, Hong DS. Engineered T-cell Receptor T Cells for Cancer Immunotherapy. *Cancer Immunol Res*. 2021 Nov; 9(11):1252-1261. PMID: 34728535 <https://doi.org/10.1158/2326-6066.CIR-21-0269>.
36. **Dumbrava EE**, Call SG, Huang HJ, Stuckett AL, Madwani K, Adat A, Hong DS, Piha-Paul SA, Subbiah V, Karp DD, Fu S, Naing A, Tsimberidou AM, Moulder SL, Koenig KH, Barcenas CH, Kee BK, Fogelman DR, Kopetz ES, Meric-Bernstam F, Janku F. PIK3CA mutations in plasma circulating tumor DNA predict survival and treatment outcomes in patients with advanced cancers. *ESMO Open*. 2021 Oct; 6(5):100230. PMID: 34479035 PMCID: PMC8414046.
37. Hegde A, Jayaprakash P, Couillault CA, Piha-Paul S, Karp D, Rodon J, Pant S, Fu S, **EI D**, Yap TA, Subbiah V, Bhosale P, Coarfa C, Higgins JP, Williams ET, Wilson TF, Lim J, Meric-Bernstam F, Sumner E, Zain H, Nguyen D, Nguyen LM, Rajapakshe K, Curran MA, Hong DS. A Phase I Dose-Escalation Study to Evaluate the Safety and Tolerability of Evofosfamide in Combination with Ipilimumab in Advanced Solid Malignancies. *Clin Cancer Res*. 2021 Jun; 27(11):3050-3060. PMID: 33771853 PMCID: PMC8172466.
38. Pairawan S, Zhao M, Yuca E, Annis A, Evans K, Sutton D, Carvajal L, Ren JG, Santiago S, Guerlavais V, Akcakanat A, Tapia C, Yang F, Bose PSC, Zheng X, **Dumbrava EI**, Aivado M, Meric-Bernstam F. First in class dual MDM2/MDMX inhibitor ALRN-6924 enhances antitumor efficacy of chemotherapy in TP53 wild-type hormone receptor-positive breast cancer models. *Breast Cancer Res*. 2021 Mar; 23(1):29. PMID: 33663585 PMCID: PMC7934277.
39. **Ileana Dumbrava, EE**. Unraveling the mysteries of microsatellite instability. *Science translational medicine*. 2021 Jan 06; 13(575) <https://doi.org/10.1126/SCITRANSLMED.ABG1757>.
40. Piha-Paul SA, **EI D**, Nair BC, Xiong W, Xu L, Mostorino R, Subbiah V, Tannir N, Fu S, Naing A, Janku F, Karp DD, Patel S, Daw NC, Hong D, Meric-Bernstam F, Zinner R. A Phase I Trial of the MET/ALK/ROS1 Inhibitor Crizotinib Combined with the VEGF Inhibitor Pazopanib in Patients with Advanced Solid Malignancies. *Onco Targets Ther*. 2021; 14:3037-3049. PMID: 33994796 PMCID: PMC8114359.
41. Mendoza T, Sheshadri A, Altan M, Hess K, George G, Stephen B, Castillo L, Rodriguez E, Gong J, Peterson C, Rodon Ahnert J, Fu S, Piha-Paul SA, Pant S, **EI D**, Yap TA, Janku F, Tsimberidou AM, Subbiah V, Karp DD, Zarifa A, McQuinn LM, Cleeland C, Hong DS, Naing A. Evaluating the psychometric properties of the Immunotherapy module of the MD Anderson Symptom Inventory. *J Immunother Cancer*. 2020 Oct; 8(2) PMID: 33097611 PMCID: PMC7590372.
42. Marcelo-Lewis KL, Moorthy S, **Ileana-Dumbrava E**. Tumor Genotype Is Shaping Immunophenotype and Responses to Immune Checkpoint Inhibitors in Solid Tumors. *J Immunother Precis Oncol*. 2020 Aug; 3(3):121-127. PMID: 35663256 PMCID: PMC9165574.
43. Naing A, Meric-Bernstam F, Stephen B, Karp DD, Hajjar J, Rodon Ahnert J, Piha-Paul SA, Colen RR, Jimenez C, Raghav KP, Ferrarotto R, Tu SM, Campbell M, Wang L, Sabir SH, Tapia C, Bernatchez C, Frumovitz M, Tannir N, Ravi V, Khan S, Painter JM, Abonofal A, Gong J, Alshawa A, McQuinn LM, Xu M, Ahmed S, Subbiah V, Hong DS, Pant S, Yap TA, Tsimberidou AM, **Dumbrava EI**, Janku F, Fu S, Simon RM, Hess KR, Varadhachary GR, Habra MA. Phase 2 study of pembrolizumab in patients with advanced rare cancers. *J Immunother Cancer*. 2020 Mar; 8(1) PMID: 32188704 PMCID: PMC7078933.
44. Owusu-Brackett N, Zhao M, Akcakanat A, Evans KW, Yuca E, **Dumbrava EI**, Janku F, Meric-Bernstam F. Targeting PI3K β alone and in combination with chemotherapy or immunotherapy in tumors with PTEN loss. *Oncotarget*. 2020 Mar; 11(No.11):961-981. PMID: 32215185 PMCID: PMC7082117.
45. Subbiah V, **Dumbrava EI**, Jiang Y, Thein KZ, Naing A, Hong DS, Fu S, Piha-Paul SA, Tsimberidou AM, Janku F, Meric-Bernstam F, Kurzrock R, Falchook G. Dual EGFR blockade with cetuximab and erlotinib combined with anti-VEGF antibody bevacizumab in advanced solid tumors: a phase 1 dose escalation triplet combination trial. *Exp Hematol Oncol*. 2020; 9:7. PMID: 32337094 PMCID: PMC7171918.
46. **Ileana Dumbrava E**, Balaji K, Raghav K, Hess K, Javle M, Blum-Murphy M, Ajani J, Kopetz S, Broaddus R, Routbort M, Demirhan M, Pant S, Tsimberidou AM, Subbiah V, Hong DS, Rodon J, Shaw K, Piha-Paul SA, Meric-Bernstam F. Targeting ERBB2 (HER2) amplification identified by next-generation sequencing in patients with advanced or metastatic solid tumors beyond conventional indications. *JCO Precision Oncology*. 2019 Oct; PMID: 32923865 PMCID: PMC7446516.
47. Owusu-Brackett N, Evans KW, Akcakanat A, Yuca E, Tapia C, Rizvi YQ, **Dumbrava EI**, Janku F, Meric-Bernstam F. TAK228 enhances antitumor activity of eribulin in triple negative breast cancer. *Oncotarget*. 2019 Aug; 10(49):5011-5019. PMID: 31489111 PMCID: PMC6707945.
48. Meric-Bernstam F, Johnson AM, **Dumbrava EEI**, Raghav K, Balaji K, Bhatt M, Murthy RK, Rodon J, Piha-Paul SA. Advances in HER2-Targeted Therapy: Novel Agents and Opportunities Beyond Breast and Gastric Cancer. *Clin Cancer Res*. 2019 Apr; 25(7):2033-2041. PMID: 30442682 PMCID: PMC6445731.

49. **Dumbrava EI**, Brusco L, Daniels M, Wathoo C, Shaw K, Lu K, Zheng X, Strong L, Litton J, Arun B, Eterovic AK, Routbort M, Patel K, Qi Y, Piha-Paul S, Subbiah V, Hong D, Rodon J, Kopetz S, Mendelsohn J, Mills GB, Chen K, Meric-Bernstam F. Expanded Analysis of Secondary Germline Findings From Matched Tumor/Normal Sequencing Identifies Additional Clinically Significant Mutations. *JCO Precis Oncol.* 2019; 3 PMID: 31517177 PMCID: PMC6741435.
50. **Ileana Dumbrava E**, Smith V, Alfattal R, El-Naggar AK, Penas-Prado M, Tsimberidou AM. Autoimmune Granulomatous Inflammation of Lacrimal Glands and Axonal Neuritis Following Treatment with Ipilimumab and Radiation Therapy. *J Immunother.* 2018 Sep; 41(7):336-339. PMID: 29787423 PMCID: PMC6086752.
51. **Ileana Dumbrava E**, Meric-Bernstam F, Yap TA. Challenges with biomarkers in cancer drug discovery and development. *Expert Opin Drug Discov.* 2018 Aug; 13(8):685-690. PMID: 29792354.
52. **Dumbrava EI**, Ivan D, Subbiah V. Hypopigmented Skin Lesions After Immunotherapy. *JAMA Oncol.* 2018 Aug; 4(8):1118-1119. PMID: 29801033 PMCID: PMC6529200.
53. Kurnit K, **El Dumbrava**, Litzenburger B, Khotskaya Y, Johnson A, Yap T, Rodon J, Zeng J, Shufean A, Bailey A, Sánchez N, Holla V, Mendelsohn J, Shaw K, Bernstam E, Mills G, Meric-Bernstam F. Precision oncology decision support: current approaches and strategies for the future. *Clinical Cancer Research.* 2018 Jun; 24(12):2719-2731. PMID: 29420224 PMCID: PMC6004235.
54. **Dumbrava EEI**, Meric-Bernstam F. Personalized cancer therapy- leveraging a knowledge base for clinical decision-making. *Cold Spring Harb Mol Case Study.* 2018 Apr; 4(2):1-9. PMID: 29212833 PMCID: PMC5880252.
55. **Ileana-Dumbrava E**, Subbiah V. Autoimmune hypophysitis. *Lancet Oncol.* 2018 Feb; 19(2):e123. PMID: 29413466.
56. **Dumbrava EI**, Alfattal R, Miller VA, Tsimberidou AM. Complete Response to a Fibroblast Growth Factor Receptor Inhibitor in a Patient With Head and Neck Squamous Cell Carcinoma Harboring FGF Amplifications. *JCO Precis Oncol.* 2018; 2 PMID: 31123723 PMCID: PMC6528487.
57. Daniels M, Wathoo C, Brusco L, Lu K, Shaw K, **Ileana Dumbrava E**, Arun B, Strong L, Litton J, Eterovic AK, Aytac U, Mendelsohn J, Mills GB, Chen K, Meric-Bernstam F. Active Disclosure of Secondary Germline Findings to Deceased Research Participants' Personal Representatives: Process and Outcomes. *JCO Precision Oncology.* E-pub ahead of print: 2017 Oct.
58. Hollebecque A, Bahleda R, Faivre L, Adam J, Poinsignon V, Paci A, Gomez-Roca C, Thery JC, Le Deley MC, Varga A, Gazzah A, **Ileana E**, Gharib M, Angevin E, Malekzadeh K, Massard C, Soria JC, Spano JP. Phase I study of temsirolimus in combination with cetuximab in patients with advanced solid tumours. *Eur J Cancer.* 2017 Aug; 81:81-89. PMID: 28618305.
59. Benajiba L, Michot JM, Baldini C, Faivre L, Varga A, Balheda R, Gazzah A, **Ileana Dumbrava E**, Postel-Vinay S, Massard C, de Botton S, Soria JC, Ribrag V. Prognostic factors and outcome of patients with hematological malignancies in phase I trials: the Gustave Roussy scoring system. *Anticancer Drugs.* 2017 Jun; 28(5):540-545. PMID: 28225458.
60. Massard C, Michiels S, Ferté C, Le Deley MC, Lacroix L, Hollebecque A, Verlingue L, **Ileana Dumbrava E**, Rosellini S, Ammari S, Ngo-Camus M, Bahleda R, Gazzah A, Varga A, Postel-Vinay S, Lorient Y, Even C, Breuskin I, Auger N, Job B, De Baere T, Deschamps F, Vielh P, Scoazec JY, Lazar V, Richon C, Ribrag V, Deutsch E, Angevin E, Vassal G, Eggermont A, André F, Soria JC. High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial. *Cancer Discov.* 2017 Jun; 7(6):586-595. PMID: 28365644.
61. Jovelet C, **Ileana Dumbrava E**, Le Deley MC, Motté N, Rosellini S, Romero A, Lefebvre C, Pedrero M, Pata-Merci N, Droin N, Deloger M, Massard C, Hollebecque A, Ferté C, Boichard A, Postel-Vinay S, Ngo-Camus M, De Baere T, Vielh P, Scoazec JY, Vassal G, Eggermont A, André F, Soria JC, Lacroix L. Circulating Cell-Free Tumor DNA Analysis of 50 Genes by Next-Generation Sequencing in the Prospective MOSCATO Trial. *Clin Cancer Res.* 2016 Jun; 22(12):2960-8. PMID: 26758560.
62. Tacher V, Le Deley MC, Hollebecque A, Deschamps F, Vielh P, Hakime A, **Ileana Dumbrava E**, Abedi-Ardekani B, Charpy C, Massard C, Rosellini S, Gajda D, Celebic A, Ferté C, Ngo-Camus M, Gousses S, Koubi-Pick V, Andre F, Vassal G, Deandreis D, Lacroix L, Soria JC, De Baère T. Factors associated with success of image-guided tumour biopsies: Results from a prospective molecular triage study (MOSCATO-01). *Eur J Cancer.* 2016 May; 59:79-89. PMID: 27017289.
63. Postel-Vinay S, Boursin Y, Massard C, Hollebecque A, **Ileana Dumbrava E**, Chiron M, Jung J, Lee JS, Balogh Z, Adam J, Vielh P, Angevin E, Lacroix L, Soria JC. Seeking the driver in tumours with apparent normal molecular profile on comparative genomic hybridization and targeted gene panel sequencing: what is the added value of whole exome sequencing? *Ann Oncol.* 2016 Feb; 27(2):344-52. PMID: 26598538.
64. Antoun S, Bayar A, **Ileana Dumbrava E**, Laplanche A, Fizazi K, di Palma M, Escudier B, Albiges L, Massard C, Lorient Y. High subcutaneous adipose tissue predicts the prognosis in metastatic castration-resistant prostate cancer patients in post chemotherapy setting. *Eur J Cancer.* 2015 Nov; 51(17):2570-7. PMID: 26278649.

65. Kossai M, Duchemann B, Boutros C, Caramella C, Hollebecque A, Angevin E, Gazzah A, Bahleda R, **Ileana Dumbrava E**, Massard C, Vielh P, Soria JC, Besse B. Antitumor activity in advanced cancer patients with thymic malignancies enrolled in early clinical drug development programs (Phase I trials) at Gustave Roussy. *Lung Cancer*. 2015 Sep; 89(3):306-10. PMID: 26160757.
66. Lorient Y, Eymard JC, Patrikidou A, **Ileana Dumbrava E**, Massard C, Albiges L, Di Palma M, Escudier B, Fizazi K. Prior long response to androgen deprivation predicts response to next-generation androgen receptor axis targeted drugs in castration resistant prostate cancer. *Eur J Cancer*. 2015 Sep; 51(14):1946-52. PMID: 26208462.
67. Patrikidou A, Lorient Y, Eymard JC, Albiges L, Massard C, **Ileana Dumbrava E**, Di Palma M, Escudier B, Fizazi K. Who dies from prostate cancer? *Prostate Cancer Prostatic Dis*. 2014 Dec; 17(4):348-52. PMID: 25311767.
68. Lorient Y, Bianchini D, **Ileana Dumbrava E**, Sandhu S, Patrikidou A, Pezaro C, Albiges L, Attard G, Fizazi K, De Bono JS, Massard C. Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100). *Ann Oncol*. 2013 Jul; 24(7):1807-12. PMID: 23576708.
69. F, Legodec J, **Maldonado Ileana E**, Greillier L, Dutau H, Ph A. Pathologie pleurale. *Revue des Maladies Respiratoires*. 2010 Jul; 2(Suppl 1):106-120.

JOURNAL ARTICLES - EDITORIALS

1. **Ileana-Dumbrava E**. Early stage EGFR-mutated lung cancer gets a targeted treatment. *Science Translational Medicine*. 2020 Oct; 12(567).
2. **Ileana-Dumbrava E**. PARP inhibitors unleash the antitumor immune response. *Science Translational Medicine*. 2020 Sep; 12(559).
3. **Ileana-Dumbrava E**. Do dendritic cells hold the key to regulating cancer antitumor immunity? *Science Translational Medicine*. 2020 Jul; 12(551).
4. **Ileana-Dumbrava E**. COVID-19 and Cancer: The bad and the ugly. *Science Translational Medicine*. 2020 May; 12(543).
5. **Ileana-Dumbrava E**. Boosting immune responses against early breast cancer. *Science Translational Medicine*. 2020 May; 12(535).
6. **Ileana-Dumbrava E**. Boosting immune responses against early breast cancer. *Science Translational Medicine*. 2020 Mar; 12(535).
7. **Ileana-Dumbrava E**, Mills GB, Yap TA. Targeting gamma secretase: has progress moved up a notch? *Ann Oncol*. 2018 Sep; 29(9):1889-1891. PMID: 30084907.

JOURNAL ARTICLES - REVIEW ARTICLES

1. **Ileana Dumbrava, EE**, Frej, KH, Sharon, E, Tawbi, H. Application and Expectations for Immune Checkpoint Blockade of LAG3 and TIGIT. *Annual Review of Medicine*. 2025 Jan 27; 76:189-205. PMID: 39656959 <https://doi.org/10.1146/annurev-med-080222-100847>.
2. Sofianidi A, **Dumbrava EE**, Syrigos KN, Nasrazadani A. Triple-Negative Breast Cancer and Emerging Therapeutic Strategies: ATR and CHK1/2 as Promising Targets. *Cancers (Basel)*. 2024 Mar 13; 16(6) PMID: 38539474 PMCID: PMC10969473.
3. Yao S, Meric-Bernstam F, Hong D, Janku F, Naing A, Piha-Paul SA, Tsimberidou AM, Karp D, Subbiah V, Yap TA, Ahnert JR, Pant S, **Dumbrava EEI**, Wathoo C, Campbell E, Yu L, Yamamura Y, Fu S. Clinical characteristics and outcomes of phase I cancer patients with CCNE1 amplification: MD Anderson experiences. *Sci Rep*. 2022 May; 12(1):8701. PMID: 35610322 PMCID: PMC9130298.
4. **Ileana Dumbrava EE**, Wistuba II, Izzo JG. From Uniplex to Multiplex Molecular Profiling in Advanced Non-Small Cell Lung Carcinoma. *Cancer J*. 2015 Sep; 21(5):413-24. PMID: 26389767.
5. Touat M, **Ileana Dumbrava E**, Postel-Vinay S, André F, Soria JC. Targeting FGFR Signaling in Cancer. *Clin Cancer Res*. 2015 Jun; 21(12):2684-94. PMID: 26078430.
6. Champiat S, **Ileana Dumbrava E**, Giaccone G, Besse B, Mountzios G, Eggermont A, Soria JC. Incorporating immune-checkpoint inhibitors into systemic therapy of NSCLC. *J Thorac Oncol*. 2014 Feb; 9(2):144-53. PMID: 24419410.
7. **Ileana Dumbrava E**, Champiat S, Soria JC. Immune-checkpoints: the new anti-cancer immunotherapies. *Bull Cancer*. 2013 Jun; 100(6):601-10. PMID: 23735730.

JOURNAL ARTICLES - CASE STUDY/STUDIES

1. Chelariu-Raicu A, Piha-Paul SA, Chavez-MacGregor M, Johnson J, Sawaya R, McAleer MF, Nguyen A, Hartnett A, Tsimberidou AM, Meric-Bernstam F, **Dumbrava EE**. Multidisciplinary Care of a Large Brain Metastasis in a Patient with Hormone-Receptor-

Positive Breast Cancer with Ataxia-Telangiectasia Mutation. *J Immunother Precis Oncol*. 2023 Aug; 6(3):158-161. PMID: 37637237 PMCID: PMC10448731.

2. **Ileana Dumbrava E**, Greillier L, Moutardier V, Barlesi F. Surgical resection of liver non-small cell lung cancer metastasis: a dual weapon? *Lung Cancer*. 2010 Nov; 70(2):221-2. PMID: 20828859.

JOURNAL ARTICLES - ABSTRACTS

1. **Dumbrava E**, Suarez-Almazor M, Painter J, Johanns TM, Dougan ML, Cappelli L, Wang Y, Bingham C, Gupta S, Warner BM, Rahma O, Naidoo J, Ott PA, Hafler DA, Kluger H, Khosroshahi A, Naqash R, Chung L, Katsumoto TR, Kummar S, Tawbi H, Sharon E. A phase 1b study of nivolumab in patients with autoimmune disorders and advanced malignancies (AIM-NIVO). *Cancer Research*. 2020 Jun; 80(16).
2. Sullivan R, Rasco D, Lim E, Sharma M, Shepard D, Patnaik A, Hamilton E, Fleming G, Papadopoulos K, ElNaggar A, Adewoye AH, Chmielowski B, **Dumbrava E**, Vaena D. COM701 demonstrates preliminary antitumor activity as monotherapy and in combination with nivolumab in patients with advanced solid tumors. *Cancer Research*. 2020 Jun; 80(16).
3. Subbiah IM, Buzdar A, **Ileana Dumbrava EE**, Fu S, Janku S, Karp DD, Naing A, Pant S, Rodon J, Tsimberidou AM, Yap TA, Subbiah V, Meric-Bernstam F, Hong DS. Investigating the disparate enrollment of older adults on phase I clinical trials: evolving participation patterns of patients 65 years and older w advanced cancer on phase I trials. *Journal of Clinical Oncology*. 2020 May; 38(15).
4. Piha-Paul SA, **Ileana-Dumbrava EE**, Janku F, Karp DD, Meric-Bernstam F, Rodon J, Ngo B, Peng P, Wu F. Phase I study of TT-00420, a multiple kinase inhibitor, in patients with triple negative breast cancers and other advanced solid tumors. *Cancer Research*. 2020 May; 80(16).
5. Naing A, Meric-Bernstam F, Stephen B, Karp DD, Hajjar J, Rodon Ahnert J, Piha-Paul SA, Colen RR, Jimenez C, Raghav KP, Ferrarotto R, Tu SM, Campbell M, Wang L, Sabir SH, Tapia C, Bernatchez C, Frumovitz M, Tannir N, Ravi V, Khan S, Painter JM, Abonofal A, Gong J, Alshawa A, McQuinn LM, Xu M, Ahmed S, Subbiah V, Hong DS, Pant S, Yap TA, Tsimberidou AM, **Dumbrava EE**, Janku F, Fu S, Simon RM, Hess KR, Varadhachary GR, Amir Habra M. Phase 2 study of pembrolizumab in patients with advanced rare cancers. *Journal for Immunotherapy of Cancer*. E-pub ahead of print: 2020 Mar; PMID: 32188704.
6. Owusu-Brackett N, Evans KW, Akcakanat A, Yuca E, Tapia C, Rizvi YQ, **El Dumbrava**, Janku F, Meric-Bernstam F. TAK228 enhances antitumor activity of eribulin in triple negative breast cancer. *Oncotarget*. E-pub ahead of print: 2019 Aug; 10(49) PMID: 31489111 PMCID: PMC6707945.
7. Yap TA, Rodon Ahnert J, Piha-Paul SA, Fu S, Janku F, Karp DD, Naing A, **Dumbrava EE**, Pant S, Subbiah S, Tsimberidou AM, Hong DS, Rose KM, Xu Q, Vellano CP, Mahendra M, Jones P, Di Francesco ME, Marszalek JR, Meric-Bernstam F. Phase I trial of IACS-010759 (IACS), a potent, selective inhibitor of complex I of the mitochondrial electron transport chain, in patients (pts) with advanced solid tumors. *J Clin Oncol*. 2019 Jun; 37.
8. Naing A, **Ileana Dumbrava E**, Murthy R, Meric-Bernstam F, Fox A, Krige D, Carter J, Champion B, Cockle P, Koetz B, McElwaine-Johnn H. A multicenter, open-label, first-in-human study of an oncolytic viral vector expressing an agonistic anti-CD40 antibody (NG-350A) in patients with epithelial tumors (FORTITUDE). *Journal of Clinical Oncology*. 2019 Jun; 37.
9. **Ileana Dumbrava EE**, Huang HJ, Stuckett A, Madwani K, Adat A, Hong DS, Piha-Paul SA, Subbiah V, Karp DD, Fu S, Naing A, Tsimberidou AM, Moulder S, Koenig K, Barcenas CH, Kee B, Fogelman D, Kopetz S, Meric-Bernstam F, Janku F. PIK3CA mutations in plasma cell-free DNA predict survival and treatment outcomes in patients with advanced cancers. *Targeting PI3K/mTOR Signaling*. 2018 Dec.
10. **Ileana Dumbrava E**, Huang HJ, Stuckett A, Madwani K, Adat A, Hong DS, Piha-Paul SA, Subbiah V, Karp D, Fu S, Naing A, Tsimberidou AM, Moulder S, Koenig K, Barcenas CH, Kee B, Fogelman D, Kopetz S, Meric-Bernstam F, Janku F. PR10 PIK3CA mutations in plasma cell-free DNA predict survival and treatment outcomes in patients with advanced cancers. 2018 Dec.
11. Owusu-Brackett, Evans KW, Akcakanat, Yuca E, **Ileana Dumbrava E**, Janku F, Meric-Bernstam F. TAK228 enhances anti-tumor activity of eribulin in triple negative breast cancer. *Oncotarget*. 2018 Dec.
12. **Ileana Dumbrava E**, Diaconu B, Tantau M, Laugier R. Efficacy of endoscopic treatment in chronic pancreatitis assessed by Izbicki Score. *Pancreatology*. 2009 May; 9:#P-103.

JOURNAL ARTICLES - OTHER

1. **Dumbrava EE**, Hanna GJ, Cote GM, et al. A phase 2 study of the MDM2 inhibitor milademetan in patients with TP53-wild type and MDM2-amplified advanced or metastatic solid tumors (MANTRA-2). *J Clin Oncol*. 2022.
2. Amorosi D, **Perspective from Dumbrava EE**. Early data from CAR macrophage trial show cell therapy is safe, feasible for solid tumors. *Hematology Oncology*. 2021 Nov.

3. Carter, Devon. Interview with Dumbrava EE - Can immunotherapy treat cancer in patients with autoimmune diseases? By Devon Carter. MD Anderson Website and Blog. 2021 Jun.
4. Carter, Devon. Interview with Dumbrava EE- Monoclonal antibodies and cancer treatment: What to know. MD Anderson Website and Blog. 2020 Nov.

BOOKS

1. **Ileana Dumbrava E.** Section 3: Molecular Targets and Pathways Handbook of Targeted Cancer Therapy and Immunotherapy. 3rd Edition ed. United States of America: Wolters Kluwer; 2022.
2. **Ileana Dumbrava E.** Section 2: Molecular Targets and Pathways Handbook of Targeted Cancer Therapy and Immunotherapy. 2nd Edition ed. United States of America: Wolters Kluwer; 2018.

BOOK CHAPTERS

1. Perkins A, **Ileana-Dumbrava E.** Targeting TGFβ/SMAD Pathway. In: Wolters Kluwer. Karp DD and Falchook GS, editor(s). 2nd ed. United States of America: 2018.
2. **Ileana-Dumbrava E.** Targeting DNA Damage Response. Handbook of Targeted Cancer Therapy and Immunotherapy. In: Wolters Kluwer. Karp DD and Falchook GS, editor(s). 2nd ed. United States of America: 2018.
3. Perkins A, **Ileana-Dumbrava E.** Targeting IGFR-1 and Insulin Receptor. In: Wolters Kluwer. Karp DD and Falchook GS, editor(s). 2nd ed. United States of America: 2018.
4. Herold J, **Ileana-Dumbrava E.** PDGFR and targeting PDGFRA. In: Wolters Kluwer. Karp DD and Falchook GS, editor(s). 2nd ed. United States of America: 2018.
5. Marcelo-Lewis K, **Ileana-Dumbrava E.** Management of Immune-Related Toxicities Handbook of Targeted Cancer Therapy. In: Wolters Kluwer. Karp DD and Falchook GS, editor(s). 2nd ed. United States of America: 2018.
6. **Ileana-Dumbrava E.** TIE receptors. In: Wolters Kluwer. Karp DD and Falchook GS, editor(s). 2nd ed. United States of America: 2018.

CONFERENCE ABSTRACTS

1. **Dumbrava EE,** Olson D, Saibil S, Pieke B, George MA, Bouvier R, Gavriliuc M, Gruber K, Moss K, Ternus N, Apostolopoulou M, Adib D, Schlechter BL. A phase I/II trial investigating safety and efficacy of autologous TAC01-HER2 in relapsed or refractory solid tumors. Proceedings of the 2023 AACR Annual Meeting 2023 Apr.
2. Holla V, Ronaghy A, Yang RK, Patel KP, Routbort MJ, Overman MJ, **Dumbrava EE,** Shaw KR, Karp DD, Meric-Bernstam F. Genomic alterations in DNA mismatch repair (dMMR). Proceedings of the 2023 AACR Annual Meeting 2023 Apr.
3. Uzunparmak B, Haymaker C, Raso G, Zhu C, Masciari S, Wang L, Kirby B, Lin H, Gorur A, A-M C, Kennon A, Ding Q, Palmieri A, Urschel GE, Yuan Y, Feng G, Rizvi Y, Hussain A, Subbiah V, Yap TA, Rodon-Ahnert J, Piha-Paul SA, Hong DS, Meric-Bernstam F, **Dumbrava EE.** HER2-low expression in patients with advanced or metastatic solid tumors. Proceedings of the 2023 AACR Annual Meeting 2023 Apr.
4. Ngoi NY, Lin HY, **Dumbrava E,** Fu S, Karp DD, Naing A, Pant S, Piha-Paul SA, Rodon J, Subbiah V, Tsimberidou AM, Campbell E, Urrutia S, Hong DS, Meric-Bernstam F, Yuan Y, Yap TA. Dynamic changes in monocyte and reticulocyte counts predict mechanism-based anemia development and recovery during ATR inhibitor treatment in phase I/II trials. Proceedings of the 2023 AACR Annual Meeting 2023 Apr.
5. Cabanas EG, Fontana E, Oberoi HK, Uboha NV, **Dumbrava EE,** Calvo E, Curigliano G, Davar D, Keenan BK, Lam VK, Manda S, Mehta A, Monchom A, Moskowitz A, Paluri R, Ribrag V, Richards D, Siu L, Swiecicki P, Wise-Draper T, Zain J, Forero-Torres A, Xu P, Ansel S. Phase 1 dose-escalation study of SGN-TGT monotherapy in patients with advanced malignancies. Proceedings of the 2023 AACR Annual Meeting 2023 Apr.
6. Nelson BE, Janku F, Fu S, **Dumbrava EI,** Hong DS, Karp D, Naing A, Rodon J, Tsimberidou A, Amaria RN, Conley A, Damodaran S, Raghav KPS, Kreider BL, Tung D, Varterasian M, Khazaie K, Piha-Paul S. Phase Ib Study of Pembrolizumab in Combination with Intratumoral Injection of Clostridium novyi-NT in Patients with Advanced Solid Tumors. Proceedings of the 2023 AACR Annual Meeting 2023 Apr.
7. Papadopoulos K, Cecchini M, Lopez JS, Jäger D, Chung KY, Platten M, Prinz F, Ishii Y, Schaer D, Gutcher I, Leder G, Pencheva R, Wagener T, Scheerans C, Zieschang C, Wagner A, Stamatelos S, **Dumbrava E.** Preliminary analysis of pharmacokinetic (PK) and target engagement biomarkers from a first in human phase 1 study of immunomodulatory aryl hydrocarbon receptor (AhR) inhibitor BAY2416964. Proceedings of the 2023 AACR Annual Meeting 2023 Apr.

8. Schlechter BL, Olson D, Saibil S, George M, Bouvier R, McKinley J, Pieke B, Geisburger J, Ternus NJ, Moss K, Adib D, **Dumbrava EE**. A Phase I/II Trial Investigating Safety and Efficacy of Autologous TAC T Cells Targeting HER2 in Relapsed or Refractory Solid Tumors. *J Immunother Cancer: Proceedings of the 2022 SITC Annual Meeting 2022 Nov*; 10(suppl 2):p. A791.
9. Henry J, Oh D, Eskew JD, Baranda J, Rodriguez Rivera II, **Dumbrava EE**, Cohen E, Belani R, McCaigue J, Shedlock DJ, Coronella J, Martin CE, Namini H, Murphy A, Ostertag EM. Phase 1 study of P-MUC1C-ALLO1 allogeneic CAR-T cells in patients with epithelial-derived cancers. *J Immunother Cancer: Proceedings of the 2022 SITC Annual Meeting 2022 Nov*; 10(suppl 2):p. A760.
10. Rasco D, **Dumbrava EE**, Sharma MR, Shepard D, Vaena D, Fleming G, Chmielowski B, Hamilton EP, Sullivan RJ, Papadopoulos KP, Patnaik A, Fophir E, Cojocar G, Bohac C, Adewoye AH, Patel MR, Overman MJ. COM701 plus nivolumab demonstrates preliminary antitumor activity and immune modulation of tumor microenvironment in patients with metastatic MSS-CRC and liver metastases. *J Immunother Cancer: Proceedings of the 2022 SITC Annual Meeting 2022 Nov*; 10(suppl 2):p. A689.
11. Yap TA, Ngoi N, **Dumbrava EE**, Karp DD, Rodon Ahnert J, Fu S, Hong DS, Naing A, Pant S, Piha-Paul SA, Subbiah V, Tsimberidou AM, Dufner D, Rhudy J, Gore S, Ivy SP, Yuan Y, Westin SN, Mills GB, Meric-Bernstam F. NCI10329: Phase Ib Sequential Trial of Agents against DNA Repair (STAR) Study to investigate the sequential combination of the Poly(ADP-Ribose) Polymerase inhibitor (PARPi) olaparib (ola) and WEE1 inhibitor (WEE1i) adavosertib (ada) in patients (pts) with DNA Damage Response (DDR)-aberrant advanced tumors, enriched for BRCA1/2 mutated and CCNE1 amplified cancers. *Eur J Cancer: Abstracts, 34th EORTC-NCI-AACR Symposium 2022 Oct*; 174(suppl 1): :p. S7.
12. Schlechter BL, **Dumbrava EE**, Olson D, Saibil S, Pieke B, Bouvier R, Moss K, Turnus N, Bader A, Adib D. A phase I/II trial investigating safety and efficacy of autologous TAC T-cells targeting HER2 in relapsed or refractory solid tumors. *Ann Oncol: Proceedings of the 2022 ESMO Congress 2022 Sep*; 33(Issue S7): :p. p. S896.
13. Ngoi NY, Lin H, **Dumbrava EE**, Fu S, Karp D, Naing A, Pant S, Rodon J, Piha-Paul SA, Subbiah V, Tsimberidou AM, Campbell E, Urrutia S, Hong DS, Meric-Bernstam F, Yuan Y, Yap TA. Correlation of clinical, genomic and hematological parameters with ATR inhibitor (ATRi) outcomes in phase I/II clinical trials. *Ann Oncol: Proceedings of the 2022 ESMO Congress 2022 Sep*; 33(Issue S7):p. S761-S762.
14. Hamid O, Sato T, Davar D, Callahan M, Thistlethwaite F, Aljumaily R, Johnson M, H-T A, **Dumbrava EE**, Izar B, Chen HA, Marshall S, Yuan Y, Deo M, Stanhope S, Collins L, Mundy R, Abdullah S, Lopez J. Results from Phase 1 dose escalation of IMC-F106C, the first PRAME × CD3 ImmTAC bispecific protein in solid tumors. *Ann Oncol: Proceedings of the 2022 ESMO Congress 2022 Sep*; 33(Issue S7):p. S875.
15. DiPeri TD, Kong K, Karp DD, Ajani JA, Pant S, Piha-Paul SA, **Dumbrava EE**, Meric-Bernstam F. Discordance of HER2 expression and/or amplification on repeat testing. *Cancer Research: Proceedings of the 113th Annual Meeting of the American Association for Cancer Research 2022 Jun*; 82(suppl 12).
16. Zhao M, DiPeri TP, Raso G, Rizvi YQ, Zheng X, Evans K, Akcakanat A, Yang F, Tripathy D, **Dumbrava EE**, Damodaran S, Meric-Bernstam F. Epigenetically upregulating TROP2 enhances therapeutic efficacy of TROP2 ADC sacituzumab govitecan. *Cancer Research: Proceedings of the 113th Annual Meeting of the American Association for Cancer Research 2022 Jun*; 82(suppl 12).
17. **Dumbrava EE**, Olson D, Schlechter BL, Saibil S, Rill D, Bader A, Adib D, Bishop M. A phase I/II trial investigating safety and efficacy of autologous TAC T cells targeting HER2 in relapsed or refractory solid tumors (TACTIC-2). *Cancer Research: Proceedings of the 113th Annual Meeting of the American Association for Cancer Research 2022 Jun*; 82(suppl 12).
18. **Dumbrava EE**, Hanna GJ, Cote GM, Stinchcombe TE, Johnson ML, Chen CT, Devarakonda SHK, Shah N, Xu F, Doebele RC, Gounder MM. A phase 2 study of the MDM2 inhibitor milademetan in patients with TP53-wild type and MDM2-amplified advanced or metastatic solid tumors (MANTRA-2). *Cancer Research: Proceedings of the 113th Annual Meeting of the American Association for Cancer Research 2022 Jun*; 82(suppl 12).
19. **Dumbrava EE**, Burton EM, Subudhi SK, Milton DR, Aparicio A, Yap TA, Naing A, Gettys Corn P, Pilie PG, Zurita AJ, Wang J, Navroze Amaria R, McQuade JL, Glitza IC, Lazar AJ, Meric-Bernstam F, Logothetis C, Davies MA, Hwu P, Tawbi HA. Phase I/II study of the selective PI3Kβ inhibitor GSK2636771 in combination with pembrolizumab in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and PTEN loss. *J Clin Oncol: Proceedings of the 2022 ASCO Annual Meeting 2022*; 40(suppl 16).
20. Alhalabi O, Tannir NM, Momin HA, Yilmaz B, Stephen B, Ejezie CL, Moyers JT, Gurses SA, How J, Fu S, Rodon Ahnert J, Hong DS, Piha-Paul SA, Subbiah V, **Dumbrava EE**, Karp DD, Janku F, Meric-Bernstam F, Naing. Phase Ib trial of selinexor (SEL) in combination with nivolumab (NIVO) alone or nivolumab plus ipilimumab (NIVO+IPI) in patients (pts) with advanced malignancies: The renal cell carcinoma (RCC) experience. *J Clin Oncol: Proceedings of the 2022 ASCO Annual Meeting 2022*; 40(suppl 16).

21. **Dumbrava EE**, Johnson ML, Tolcher AW, Shapiro G, Thompson JA, El-Khoueiry AB, Vandross AL, Kummar S, Parikh AR, Munster PN, Daly E, De Leon L, Khaddar M, LeDuke K, Robell K, Sheehan LI, St Louis M, Wiebesiek A, Alland L, Schram AM. First-in-human study of PC14586, a small molecule structural corrector of Y220C mutant p53, in patients with advanced solid tumors harboring a TP53 Y220C mutation. *J Clin Oncol: Proceedings of the 2022 ASCO Annual Meeting 2022*; 40(suppl 16).
22. McKean M, **Dumbrava EE**, Hamid O, Merriam P, Mettu NB, Call JA, Kapoun AM, Lucas J, Seetharam M, Vaishampayan UN, Veroha SJ, Krishnan S, George AJ. Safety and efficacy of etigilimab in combination with nivolumab in select recurrent/advanced solid tumors. *J Clin Oncol: Proceedings of the 2022 ASCO Annual Meeting 2022*; 40(suppl 16).
23. Piha-Paul SA, Xu B, Singh Raghav KP, Meric-Bernstam F, Janku F, **Dumbrava EE**, Fu S, Karp DD, Rodon Ahnert J, Conley AP, Mott F, Ajani JA, Hong DS, Fan Y, Peng P, Levin WJ, Ngo B, Ru QC, Wu F, Javle MM. First-in-human, phase I study of TT-00420, a multiple kinase inhibitor, as a single agent in advanced solid tumors. *J Clin Oncol: Proceedings of the 2022 ASCO Annual Meeting 2022*; 40(suppl 16).
24. **Dumbrava EE**, Hanna GJ, Cote GM, Stinchcombe T, Johnson ML, Chen C, Devarakonda S, Shah N, Xu F, Doebele RC, Gounder MM. A phase 2 study of the MDM2 inhibitor milademetan in patients with TP53-wild type and MDM2-amplified advanced or metastatic solid tumors (MANTRA-2). *J Clin Oncol: Proceedings of the 2022 ASCO Annual Meeting 2022*; 40(suppl 16).
25. Ngoi N, Lin HY, **Dumbrava EE**, Fu S, Karp DD, Naing A, Pant S, Piha-Paul SA, Rodon Ahnert J, Subbiah V, Tsimberidou AM, Campbell E, Hong DS, Meric-Bernstam F, Yuan Y, Yap TA. Baseline predictors of hematological toxicity in patients with advanced cancer treated with ATR inhibitors in phase I/II clinical trials. *J Clin Oncol: Proceedings of the 2022 ASCO Annual Meeting 2022*; 40(suppl 16).
26. Nelson BE, Saleem S, Damodaran S, Somaiah N, Piha-Paul SA, More JA, Yilmaz B, Karp DD, **Dumbrava EE**, Tsimberidou AM, Hong DS, Rodon Ahnert J, Booser DJ, Ibrahim NK, Conley AP, Bhosale P, Rojas Hernandez CM, Tripathy D, Naing A, Meric-Bernstam F. Phase Ib study of selinexor and eribulin combination in advanced solid tumors and triple-negative breast cancer. *J Clin Oncol: Proceedings of the 2022 ASCO Annual Meeting 2022*; 40(suppl 16).
27. Nelson BE, Andersen C, Yuan Y, Hong DS, Naing A, Karp DD, Yap TA, Rodon Ahnert J, Campbell E, Tsimberidou AM, **Dumbrava EE**, Fu S, Piha-Paul SA, Pant S, Blumenschein GR, Altan M, Tawbi HA, Tannir NM, Meric-Bernstam F, Subbiah V. Effect of immunotherapy and time-of-day infusion chronomodulation on survival in advanced cancers. *J Clin Oncol: Proceedings of the 2022 ASCO Annual Meeting 2022*; 40(suppl 16).
28. Coleman N, DiPeri TP, Nguyen D, Naing A, Piha-Paul SA, Tsimberidou AM, Zheng X, Johnson A, Wang W, Shaw KR, **Dumbrava EE**, Fu S, Rodon J, Rodon Ahnert J, Hong DS, Subbiah V, Yap TA, Luthra R, Patel KP, Meric-Bernstam F. Repeat large panel genomic sequencing identifies actionable alterations and characterizes the genomic landscape in patients with metastatic solid tumors. *J Clin Oncol: Proceedings of the 2022 ASCO Annual Meeting 2022*; 40(suppl 16).
29. Davar D, Ribrag V, Sarkozy C, Garralda E, Kumar Oberoi H, Mehta A, Curigliano G, Belli C, Zain J, Herrera A, Sanborn R, **Dumbrava E Forero-Torres A**, Ansell S. Phase 1 Study Of SEA-TGT, A Human, Nonfucosylated Anti-Tigit Monoclonal Antibody With Enhanced Immune-Effector Function, In Patients With Advanced Malignancies (Sgntgt-001, Trial In Progress). *J Immunother Cancer: SITC 36th Anniversary Annual Meeting 2021 Nov*; 9(suppl 2).
30. Fu S, Yao S, Yuan Y, Previs RA, Elias AD, Carvajal R, George TJ, Yuan Y, Yamamura Y, Westin S, Xing Y, **Ileana Dumbrava EE**, Karp DD, Piha-Paul SA, Tsimberidou AM, Rodon J, Takebe N, Kunos C, Lu K, Keyomarsi K, Meric-Bernstam F. Phase II trial of the Wee1 inhibitor adavosertib in advanced refractory solid tumors with CCNE1 amplification. *Cancer Res 2021 Jun*; 81(suppl 13).
31. Sharma MR, Carvajal RD, Catenacci D, Emens LA, Hanna GJ, Juric D, Y-K K, Lee J, K-W L, Li BT, Moore K, Pegram MD, Pohlmann PR, Rasco D, Spira A, Heeke AL, Wang D, Garbo L, Manda S, Sachdev J, Ackerman SE, LeBlanc H, Dornan D, Kowaneta M, Alonso MN, Husain A, Perez EA, **Dumbrava EE**. Phase 1/2 study of a novel HER2 targeting TLR7/8 immune-stimulating antibody conjugate (ISAC), BDC-1001, alone and in combination with pembrolizumab (pembro) in patients (pts) with HER2-expressing advanced solid tumors. *Cancer Res 2021 Jun*; 81(suppl 13).
32. **Dumbrava EE**, Mahipal A, Gao X, Shapiro G, Starr JS, Singh P, Furqan M, Ahrorov A, Hickman D, Gubits A, Attar EC, Awad MM, Das S, Park H. Phase 1/2 study of eprenetapopt (APR-246) in combination with pembrolizumab in patients with solid tumor malignancies. *J Clin Oncol 2021*; 39(suppl 15).
33. Sharma M, Carvajal RD, Hanna GJ, Li BT, Moore KN, Pegram MD, Rasco DW, Spira AI, Alonso M, Fang L, Husain A, Perez EA, **Dumbrava EE**. Preliminary results from a phase 1/2 study of BDC-1001, a novel HER2 targeting TLR7/8 immune-stimulating antibody conjugate (ISAC), in patients (pts) with advanced HER2-expressing solid tumors. *J Clin Oncol 2021*; 39(suppl 15).

34. Park H, Shapiro G, Gao X, Mahipal A, Starr J, Furqan M, Singh P, Ahrorov A, Hickman D, Gallacher PD, Attar EC, Awad MM, Das S, **Dumbrava EE**. Phase 1/2 study of Eprenetapopt (APR-246) in Combination with Pembrolizumab in Patients with Solid Tumor Malignancies. *Ann Oncol* 2021; 32(suppl 5):S586.
35. Robert F, **Dumbrava EE**, Xing Y, Mills E, Freddo JL, Theuer CP, Adams BJ, Lawrence J, Trigeiro AA, Xu C, Meng Y, Lee L, Zhao Y, Wang J, Shen HJ, Gordon MS. Preliminary safety, pharmacokinetics (PK), pharmacodynamics (PD) and clinical efficacy of uliledlimab (TJ004309), a differentiated CD73 antibody, in combination with atezolizumab in patients with advanced cancer. *J Clin Oncol* 2021; 39(suppl 15).
36. **Dumbrava EE**, Shapiro G, Bendell JC, Yap TA, Jeselsohn R, Lepley DM, Hurley S, Lin KK, Liao M, Habeck J, Enke A, Hamilton EP. Phase 1b/2 SEASTAR trial: Safety, pharmacokinetics, and preliminary efficacy of the poly(ADP)-ribose polymerase (PARP) inhibitor rucaparib and angiogenesis inhibitor lucitanib in patients with advanced solid tumors. *J Clin Oncol* 2021; 39(suppl 15).
37. Govindan R, Townsend AR, Miller KD, Mehmi I, Kuboki Y, **Dumbrava EE**, Hamilton EP, Vuu I, Rasmussen E, Mileskin LR, Genta S, Iwata H, Adams S, Fujii H, Chawla SP. Trial in progress: A phase 1, multicenter, open-label, dose-exploration and dose-expansion study evaluating the safety, tolerability, pharmacokinetics, and efficacy of AMG650 in subjects with advanced solid tumors. *J Clin Oncol* 2021; 39(suppl 15).
38. Burton E, **Dumbrava EE**, Peng W, Milton D, Amaria R, Mcquade J, Glitza IC, Hong D, Patel S, Rodon J, Yap TA, Naing A, Piha-Paul SA, Balmes G, Lazar A, Meric-Bernstam F, Hwu P, Davies MA, Tawbi HA. Ph I/II study of PI3K- β inhibitor GSK2636771 (G771) in combination with pembrolizumab (P) in patients (pts) with PTEN loss and melanoma or other advanced solid tumors. *Ann Oncol* 2021; 32(suppl 5).
39. Moyers J, Nguyen D, Hong DS, **Dumbrava EE**, Fu S, Karp D, Naing A, Pant S, Janku F, Piha-Paul S, Rodon J, Subbiah V, Tsimberidou AM, Meric-Bernstam F, Yap TA. Adherence to the Food and Drug Administration (FDA) Guidance for the Co-Development of Two or More Investigational New Drugs in Phase 1/2 Cancer Trials. *Ann Oncol* 2021; 32(suppl 5).
40. Coleman N, Naing A, Zhang S, Piha-Paul SA, Tsimberidou AM, Janku F, Rodon J, Pant S, **Dumbrava EE**, Fu S, Hong DS, Meric-Bernstam F, Subbiah V. Phase I study of mTORC1/2 inhibitor sapanisertib (TAK-228) in combination with metformin in patients (pts) with mTOR/AKT/PI3K pathway alterations and advanced solid malignancies. *J Clin Oncol* 2021; 39(suppl 15).
41. Vaena DA, Fleming GF, Chmielowski B, Sharma M, Hamilton EP, Sullivan RJ, Shepard DR, Papadopoulos KP, Patnaik A, ElNaggar A, Adewoye AH, Smith R, Lim EA, **Dumbrava EE**, Rasco DW. COM701 with or without nivolumab: Results of an ongoing phase 1 study of safety, tolerability and preliminary antitumor activity in patients with advanced solid malignancies (NCT03667716). *J Clin Oncol* 2021; 39(suppl 15).
42. Abo-Zahrah R, Karp DD, Adat A, Yap TA, Fu S, Rodon Ahnert J, Piha-Paul SA, Tsimberidou AM, Naing A, Subbiah V, **Dumbrava EE**, Overman MJ, Patel SP, Amaria RN, Westin SN, Meric-Bernstam F, Janku F. Patients with advanced solid cancers treated with ERK inhibitors exhibit pseudo-progression in lymphatic nodes. *J Clin Oncol* 2021; 39(suppl 5).
43. Yap TA, **Dumbrava EE**, Rodon Ahnert J, Hong DS, Pant S, Karp DD, Piha-Paul SA, Subbiah V, Tsimberidou AM, Fu S, Janku F, Montez S, Ahmad-Taha MT, Guerrero D, Nazarenko NN, Moore Y, Soth M, Kovacs J, Heffernan TP, Jones P. First-in-human biomarker-driven phase I trial of the potent and selective glutaminase-1 (GLS1) inhibitor IACS-6274 (IPN60090) in patients (pts) with molecularly selected advanced solid tumors. *J Clin Oncol* 2021; 39(suppl 15).
44. Piha-Paul SA, Xu B, Janku F, **Dumbrava EE**, Fu S, Karp DD, Meric-Bernstam F, Hong DS, Rodon JA, Tsimberidou AM, Javle MM, Fan Y, Peng P, Levin WJ, Ngo B, Wang H, Sun C, Ru QC, Wu F. Phase I study of TT-00420, a multiple kinase inhibitor, as a single agent in advanced solid tumors. *J Clin Oncol* 2021; 39(suppl 15).
45. **E ID**, Sharma MR, Carvajal RD, Catenacci D, Emens LA, Gadgeel SM, Hanna GJ, Dejan Juric D, Kang YK, Lee J, Lee KW, Li BT, Moore K, Pegram MD, Pohlmann PR, Rasco D, Spira A, Tan AR, Ackerman SE, LeBlanc H, Dornan D, Kowanetz M, Alonso MN, Perez EA. Phase 1/2 study of a novel HER2 targeting TLR7/8 immune-stimulating antibody conjugate (ISAC), BDC-1001, as a single agent and in combination with an immune checkpoint inhibitor in patients with advanced HER2-expressing solid tumors. *Cancer Research* 2020 Dec; 81(suppl 4).
46. Sharma MR, **Ileana Dumbrava E**, Carvajal RD, Catenacci DV, Emens LA, Hanna GJ, Juric D, Kang YK, Lee J, Lee KW, Li BT, Moore KN, Pegram MD, Pohlmann PR, Rasco D, Spira AI, Tan A, Wang D, Ackerman SE, LeBlanc HN, Dornan D, Kowanetz M, Alonso MN, Perez EA. Phase 1/2 study of novel HER2-targeting, TLR7/8 immune-stimulating antibody conjugate (ISAC) BDC-1001 with or without immune checkpoint inhibitor in patients with advanced HER2-expressing solid tumors. *Journal for ImmunoTherapy of Cancer* 2020 Nov; 8(Suppl 3).
47. Hong DS, Butler MO, Russell Pachynski R, Sullivan RJ, Kebriaei P, Boross-Harmer S, Frigault MJ, **Dumbrava E**, Sauer A, Brophy F, Navenot JM, Fayngerts S, Bai J, Norry E, Fracasso PG. Phase I clinical trial evaluating the safety of ADP-A2M10 in patients

- with MAGE-A10+ head and neck, melanoma, or urothelial tumors. *Journal for ImmunoTherapy of Cancer* 2020 Nov; 8(Suppl 3).
48. Yap TA, Hamilton EP, Bauer TM, **Ileana Dumbrava EE**, Jeselsohn R, Enke A, Hurley S, Lin KK, Wride K, Giordano H, Shapiro G. Rucaparib + sacituzumab govitecan (SG): Initial data from the phase Ib/II SEASTAR study (NCT03992131). *Annals of Oncology* 2020 Sep; 31(Supplement 4).
 49. Fu S, Hong D, Fogelman D, Shaikh F, Dupont-Roettger D, Bisdas S, **Ileana Dumbrava EE**, Piha-Paul S, Liu S, Dugourd D, Yamamura Y. A phase Ib study on a TRPV6-inhibitor, SORC13 in patients with advanced solid tumours. *Annals of Oncology* 2020 Sep; 31(Supplement 4).
 50. Pilie PG, Gheeya JS, Kyewalabye K, Goswamy RV, Wani KM, Le H, Campbell E, Sanchez NS, Yang D, Garmezzy B, **EE ID**, Rodon Ahnert J, Heffernan T, Holla V, Shaw KR, Meric-Bernstam F, Lazar AJ, Wang W, Yap TA. Identifying functional loss of ATM gene in patients with advanced cancer. *Journal of Clinical Oncology* 2020 May; 38(suppl 15).
 51. **EE ID**, Suarez-Almazor ME, Painter J, Johanns T, Dougan ML, Cappelli L, Bingham CO, Wang Y, Gupta S, Warner BM, Rahma OE, Naidoo J, Ott PA, Hafler DA, Kluger HM, Khosroshahi A, Katsumoto TR, Kummar S, Sharon E, Abdul-Hassan Tawbi H. A phase Ib study of nivolumab in patients with autoimmune disorders and advanced malignancies (AIM-NIVO). *J Clin Oncol* 2020; 38(suppl 15).
 52. Pairawan SS, Yuca E, Evans K, Annis A, Narasimhan N, Sutton D, Carvajal LA, J-G R, Santiago S, Guerlavais V, Akcakanat A, Tapia C, **Ileana Dumbrava E**, Aivado M, Meric-Bernstam F. The stapled peptide ALRN-6924, a dual inhibitor of MDMX and MDM2, enhances antitumor efficacy of paclitaxel and Nab-paclitaxel in TP53 wild-type MCF-7 breast cancer models. *Cancer Research* 2019 Feb; 79(Suppl 4):pp. P6-20-11.
 53. Owusu-Brackett N, Zhao M, Akcakanat A, Evans KW, Yuca E, Tapia C, **Ileana Dumbrava E**, Janku F, Meric-Bernstam F. Targeting PI3K β alone and in combination with chemotherapy or immunotherapy in tumors with PTEN loss. 2018 San Antonio Breast Cancer Symposium 2019 Feb; Volume 79(4 Suppl):pp. P6-21-04.
 54. **Ileana Dumbrava E**, Balaji K, Raghav K, Javle M, Blum-Murphy M, Sajan B, Kopetz S, Broaddus R, Routbort M, Pant S, Tsimberidou A, Subbiah V, Hong D, Rodon J, Shaw K, Piha-Paul S, Meric-Bernstam F. Targeting HER2 (ERBB2) amplification identified by next-generation sequencing (NGS) in patients with advanced or metastatic solid tumors. *Mol Cancer Ther* 2018 Jan; 17(1 Suppl):#A167.
 55. **Ileana Dumbrava E**, Brusco L, Daniels MS, Wathoo C, Shaw K, Lu K, Zheng X, Strong LC, Litton J, Arun B, Eterovic A, Routbort M, Piha-Paul S, Subbiah V, Hong DS, Kopetz S, Mendelsohn J, Yap T, Mills CB, Chen K, Meric-Bernstam F. Prevalence of incidental germline pathogenic (PV) and likely pathogenic (LPV) variants in hereditary cancer-related genes identified in matched tumor/normal sequencing of advanced solid tumors. *J Clin Oncol* 2017 May; 35(15 Suppl):#1524.
 56. **Ileana Dumbrava E**, Brusco L, Daniels MS, Wathoo C, Shaw K, Lu K, Zheng X, Strong LC, Litton J, Arun B, Eterovic A, Piha-Paul S, Subbiah V, Hong DS, Woodman S, Mendelsohn J, Yap T, Mills CB, Chen K, Meric-Bernstam F. Pathogenic variants in DNA damage response (DDR) genes in patients with advanced solid tumors. *J Clin Oncol* 2017 May; 35(15 Suppl):#11567.
 57. Shien K, Ruder D, **Ileana Dumbrava E**, Papadimitrakopoulou VA, Frampton GM, Behrens C, Kalhor N, Lee JJ, Tang X, Herbst RS, Wistuba II, Izzo JG. Detection of a novel ALK fusion variant in lung adenocarcinoma using a comprehensive genomic analysis. *Cancer Research* 2016 Jul; 76(suppl 14):pp. 1144.
 58. **Ileana Dumbrava E**, Jovelet C, Le Deley MC, Massard C, Motté N, Hollebecque A, Boichard A, Ferté C, Postel-Vinay S, Rosellini S, Ngo-Camus M, De Baere T, Vielh P, Richon C, Laporte M, Gouisse S, Loriot Y, Bahleda R, Gazzah A, Varga A, Vassal G, Eggermont A, André F, Soria JC, Lacroix L. Circulating cell-free tumor DNA (cfDNA) analysis of 50-genes by next-generation sequencing (NGS) in the prospective MOSCATO trial. *Cancer Res* 2015 Aug; 75(15 Suppl):#2401.
 59. Ferté C, Massard C, **Ileana Dumbrava E**, Hollebecque A, Lacroix L, Ammari S, Ngo-Camus M, Bahleda R, Gazzah A, Varga A, Postel-Vinay S, Loriot Y, Auger N, Koubi-Pick V, Job B, De Baere T, Deschamps F, Vielh P, Lazar V, Le Deley MC, Richon C, Ribrag V, Deutsch E, Angevin E, Vassal G, Eggermont A, André F, Soria JC. Molecular screening for cancer treatment optimization (MOSCATO 01): a prospective molecular triage trial; Interim analysis of 420 patients. *Cancer Res* 2014 Oct; 74(19 Suppl):#CT240.
 60. **Ileana Dumbrava E**, Antoun S, Albiges L, Massard C, Di Palma M, Escudier B, Fizazi K, Loriot Y. Effects of abiraterone acetate and enzalutamide on muscle and adipose mass in men with metastatic castration-resistant prostate cancer (mCRPC). *J Clin Oncol: Proceedings of the ASCO Annual Meeting* 2013 Jun; 31(Suppl 15):#5088.
 61. Bianchini D, Loriot Y, **Ileana Dumbrava E**, Sandhu S, Pezaro C, Albiges L, Attard G, Fizazi K, de Bono JS, Massard C. Abiraterone in patients with metastatic castration-resistant prostate cancer progressing after docetaxel and MDV3100: a multicentre study. *Annals of Oncology* 2012 Sep; 23(Suppl 9):#924P.

62. **Ileana Dumbrava E**, Maldonado F, Astoul P. Where did my central line go? The pinch-off syndrome. Cancer Imaging 2010; 10(Suppl):#200.

Legend: 1 = Co-first authors, 2 = Co-second authors, L = Co-last authors, * = Trainee, ✉ = Corresponding author

Last updated: June 05, 2025